<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">mdPmDx5ksLPxymJyPvLfFmj</article-id>
      <article-id pub-id-type="other">00013</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000200013</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200213</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000200013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Remodela&#231;&#227;o ventricular p&#243;s-infarto do mioc&#225;rdio: conceitos e implica&#231;&#245;es cl&#237;nicas</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zornoff</surname>
            <given-names>Leonardo A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paiva</surname>
            <given-names>Sergio A. R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duarte</surname>
            <given-names>Daniella R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spadaro</surname>
            <given-names>Joel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>02</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>2</issue>
      <fpage>157</fpage>
      <lpage>164</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>06</day>
        <month>04</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>Remodela&#231;&#227;o ventricular p&#243;s-infarto do mioc&#225;rdio: conceitos e implica&#231;&#245;es cl&#237;nicas</p>
    <p>
      <bold>Leonardo A. M. Zornoff; Sergio A. R. Paiva; Daniella R. Duarte; Joel Spadaro</bold>
    </p>
    <p> Faculdade de Medicina de Botucatu, SP -Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Remodela&#231;&#227;o ventricular, infarto do mioc&#225;rdio, isquemia mioc&#225;rdica, disfun&#231;&#227;o ventricular.</p>
    <p>Ap&#243;s infarto agudo do mioc&#225;rdio, o processo de remodela&#231;&#227;o se caracteriza, clinicamente, por aumento da cavidade ventricular. Na fase aguda, a dilata&#231;&#227;o ventricular &#233; conseq&#252;&#234;ncia do processo de expans&#227;o do infarto, enquanto a dilata&#231;&#227;o cavit&#225;ria tardia &#233; conseq&#252;&#234;ncia do processo de hipertrofia exc&#234;ntrica.</p>
    <p>A remodela&#231;&#227;o ventricular desempenha papel fundamental na fisiopatologia da disfun&#231;&#227;o do ventr&#237;culo, ap&#243;s o infarto. Ao reagir a determinada agress&#227;o, as altera&#231;&#245;es gen&#233;ticas, estruturais e bioqu&#237;micas desse processo v&#227;o resultar em deteriora&#231;&#227;o da capacidade funcional do cora&#231;&#227;o, em longo prazo, e conseq&#252;ente aparecimento dos sinais e sintomas de insufici&#234;ncia card&#237;aca e/ou morte s&#250;bita. Os mecanismos propostos para explicar o aparecimento da disfun&#231;&#227;o ventricular s&#227;o complexos, mas destacam-se: modifica&#231;&#245;es no tr&#226;nsito de c&#225;lcio, altera&#231;&#245;es da via beta-adren&#233;rgica, altera&#231;&#245;es das prote&#237;nas contr&#225;teis, aumento da morte celular, ac&#250;mulo de col&#225;geno, altera&#231;&#245;es das metaloproteases, aumento do estresse oxidativo, d&#233;ficit energ&#233;tico, altera&#231;&#245;es das prote&#237;nas do citoesqueleto, da membrana e da matriz e altera&#231;&#245;es da geometria ventricular. Adicionalmente, a remodela&#231;&#227;o est&#225; associada a maior preval&#234;ncia de ruptura card&#237;aca, arritmias e forma&#231;&#227;o de aneurismas, ap&#243;s o infarto.</p>
    <p>A remodela&#231;&#227;o, portanto, est&#225; associada a pior progn&#243;stico p&#243;s-infarto. Desse modo, o entendimento desse processo &#233; cr&#237;tico, pois a evolu&#231;&#227;o da remodela&#231;&#227;o pode ser modificada por meio de diversas interven&#231;&#245;es terap&#234;uticas. </p>
    <p>
      <bold>Hist&#243;rico</bold>
    </p>
    <p>O termo remodela&#231;&#227;o, remodelamento ou remodelagem, foi usado, pela primeira vez em rela&#231;&#227;o &#224; isquemia mioc&#225;rdica, em 1982, por Hockman e Buckey, em discuss&#227;o sobre a substitui&#231;&#227;o do tecido necr&#243;tico infartado por tecido cicatricial<sup>1</sup>. Em 1985, Janice Pfeffer foi a primeira pesquisadora a utilizar o termo remodela&#231;&#227;o no contexto atual. No modelo de infarto experimental em ratos, remodela&#231;&#227;o foi usada para caracterizar o aumento da cavidade ventricular esquerda<sup>2</sup>. Nos anos seguintes, a palavra foi utilizada, esporadicamente, em artigos sobre altera&#231;&#245;es morfol&#243;gicas ap&#243;s o infarto agudo do mioc&#225;rdio (IAM). Em 1990, Pfeffer e Braunwald<sup>3</sup> publicaram revis&#227;o sobre a remodela&#231;&#227;o ap&#243;s o IAM, e a express&#227;o foi cunhada para caracterizar altera&#231;&#245;es morfol&#243;gicas ap&#243;s o infarto, caracteristicamente o aumento da cavidade ventricular. Nesse artigo, os autores enfatizavam que o processo de remodela&#231;&#227;o resultava em disfun&#231;&#227;o ventricular<sup>3</sup>. Nos anos seguintes, o termo remodela&#231;&#227;o foi amplamente aplicado, abrangendo grande variedade de situa&#231;&#245;es cl&#237;nicas. Em 2000, ocorreu f&#243;rum internacional que definiu a remodela&#231;&#227;o como varia&#231;&#245;es moleculares, celulares e intersticiais card&#237;acas, que v&#227;o se manifestar clinicamente por altera&#231;&#245;es no tamanho, massa, geometria e fun&#231;&#227;o do cora&#231;&#227;o, em resposta a determinada agress&#227;o (<xref ref-type="fig" rid="fig01">fig. 1</xref>)<sup>4,5</sup>.</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf01.jpg"/></fig>
    <p>
      <bold>Caracteriza&#231;&#227;o da remodela&#231;&#227;o p&#243;s-IAM</bold>
    </p>
    <p>Simultaneamente &#224; necrose das miofibrilas, h&#225; desintegra&#231;&#227;o do col&#225;geno interfibrilar. A perda desse tecido de sustenta&#231;&#227;o torna a regi&#227;o mais propensa a distens&#227;o e, conseq&#252;entemente, mais suscet&#237;vel a deforma&#231;&#245;es. Assim, pode ocorrer deslizamento de &#225;reas musculares necr&#243;ticas, com realinhamento dos mi&#243;citos na parede infartada. Como conseq&#252;&#234;ncia, h&#225; afilamento da regi&#227;o atingida e dilata&#231;&#227;o da cavidade. Essa dilata&#231;&#227;o ventricular aguda, caracterizada por adelga&#231;amento e distens&#227;o da parede infartada, &#233; denominada expans&#227;o do infarto<sup>1,6</sup>.</p>
    <p>Cronicamente, deve-se considerar que, em cora&#231;&#245;es normais, tanto a tens&#227;o sist&#243;lica como a diast&#243;lica s&#227;o m&#225;ximas na regi&#227;o medial do ventr&#237;culo, de valor intermedi&#225;rio na base e m&#237;nima no &#225;pice. J&#225; em cora&#231;&#245;es infartados, conseq&#252;entemente &#224; expans&#227;o, o ventr&#237;culo perde sua forma el&#237;ptica normal, assumindo configura&#231;&#227;o esf&#233;rica. Nesse novo formato, h&#225; aumento importante da tens&#227;o parietal no &#225;pice, de forma a igual&#225;-la aos valores da regi&#227;o medial, embora aqui tamb&#233;m ocorra aumento de seus valores. Al&#233;m dessa redistribui&#231;&#227;o de for&#231;as, verifica-se aumento significativamente maior da tens&#227;o parietal na di&#225;stole do que na s&#237;stole. Acredita-se que o aumento desse estresse estimularia a replica&#231;&#227;o dos sarc&#244;meros, preferencialmente em s&#233;rie. Comumente, em raz&#227;o da intera&#231;&#227;o desses fatores, a rela&#231;&#227;o raio da cavidade/espessura da parede aumenta, caracterizando a hipertrofia ventricular do tipo exc&#234;ntrica<sup>3,4,7</sup>. Assim, essa dilata&#231;&#227;o ventricular cr&#244;nica, secund&#225;ria &#224; hipertrofia exc&#234;ntrica, seria uma adapta&#231;&#227;o que permitiria a manuten&#231;&#227;o da fun&#231;&#227;o ventricular, em contraposi&#231;&#227;o ao aumento do estresse parietal (<xref ref-type="fig" rid="fig02">fig. 2</xref>).</p>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf02.jpg"/></fig>
    <p>Dessa forma, ap&#243;s o infarto agudo do mioc&#225;rdio, o processo de remodela&#231;&#227;o se caracteriza, clinicamente, por aumento da cavidade ventricular. Na fase aguda, a dilata&#231;&#227;o ventricular &#233; conseq&#252;&#234;ncia do processo de expans&#227;o do infarto, enquanto a dilata&#231;&#227;o cavit&#225;ria tardia &#233; conseq&#252;&#234;ncia do processo de hipertrofia exc&#234;ntrica.</p>
    <p>
      <bold>Conseq&#252;&#234;ncias da remodela&#231;&#227;o</bold>
    </p>
    <p>Na fase aguda do IAM, em decorr&#234;ncia do afilamento e crescimento da parede infartada, prevalece o conceito de que a referida expans&#227;o predisp&#245;e ao aparecimento de ruptura ventricular, bem como representa o substrato anat&#244;mico para a posterior forma&#231;&#227;o de aneurismas<sup>3</sup>.</p>
    <p>Em rela&#231;&#227;o aos aspectos funcionais, devemos considerar que ap&#243;s o IAM, em decorr&#234;ncia da perda de tecido muscular, &#233; comum ocorrer queda do volume ejetado, com aumento do volume sist&#243;lico final e diast&#243;lico final do VE. Esse processo resulta em aumento da tens&#227;o diast&#243;lica (pr&#233;-carga) e dilata&#231;&#227;o ventricular. Pela a&#231;&#227;o do mecanismo de Frank-Starling, a contratilidade tende a ser restaurada, restabelecendo, numa fase inicial, as press&#245;es de enchimento ventricular.</p>
    <p>Cronicamente, entretanto, o processo de remodela&#231;&#227;o ventricular desempenha papel fundamental na fisiopatologia da disfun&#231;&#227;o ventricular. Ao reagir a determinada inj&#250;ria, as altera&#231;&#245;es gen&#233;ticas, estruturais e bioqu&#237;micas desse processo v&#227;o resultar em deteriora&#231;&#227;o da capacidade funcional do cora&#231;&#227;o, em longo prazo, e conseq&#252;ente aparecimento dos sinais e sintomas de insufici&#234;ncia card&#237;aca e/ou morte s&#250;bita<sup>3-5,7</sup>. </p>
    <p>Apesar de prevalecer o conceito de que a remodela&#231;&#227;o ventricular resulte em deteriora&#231;&#227;o progressiva da fun&#231;&#227;o ventricular, os mecanismos respons&#225;veis por esse fen&#244;meno ainda n&#227;o est&#227;o completamente esclarecidos. Independentemente do est&#237;mulo, uma das caracter&#237;sticas mais marcantes da remodela&#231;&#227;o &#233; a modifica&#231;&#227;o do padr&#227;o de express&#227;o de diversas prote&#237;nas, com o aumento ou a re-express&#227;o de genes do per&#237;odo fetal. As causas e as poss&#237;veis vantagens ou desvantagens desse comportamento ainda n&#227;o est&#227;o suficientemente esclarecidas. Aceita-se, entretanto, que a express&#227;o gen&#233;tica fetal seja tanto um marcador quanto possa estar relacionada aos mecanismos propriamente envolvidos na progress&#227;o do processo de remodela&#231;&#227;o, at&#233; o aparecimento da disfun&#231;&#227;o ventricular<sup>5,8</sup>. </p>
    <p>A seguir, ser&#227;o discutidos alguns dos potenciais fatores envolvidos na deteriora&#231;&#227;o progressiva da fun&#231;&#227;o ventricular, no cora&#231;&#227;o remodelado.</p>
    <p>
      <bold>Tr&#226;nsito de c&#225;lcio</bold>
    </p>
    <p>O tr&#226;nsito de c&#225;lcio pelo ret&#237;culo sarcoplasm&#225;tico &#233; um processo ativo, complexo, que envolve a participa&#231;&#227;o de v&#225;rios componentes. Por exemplo, sistemas de membrana e intracelulares de c&#225;lcio (canais tipo-L, rianodina, calsequestrina) regulam a quantidade de c&#225;lcio ofertado &#224;s prote&#237;nas contr&#225;teis durante o processo de contra&#231;&#227;o. Da mesma forma, a ativa&#231;&#227;o da calmodulina quinase e a fosforila&#231;&#227;o da fosfolambam estimulam enzimas (SR-Ca<sup>++</sup>-ATPase ou SERCA-2) respons&#225;veis pela maior capta&#231;&#227;o de c&#225;lcio pelo ret&#237;culo sarcoplasm&#225;tico, promovendo melhora do relaxamento<sup>9</sup>. </p>
    <p>Em situa&#231;&#245;es de remodela&#231;&#227;o e disfun&#231;&#227;o ventricular, existem evid&#234;ncias de diversas altera&#231;&#245;es no tr&#226;nsito de c&#225;lcio, como modifica&#231;&#245;es dos canais-L, receptores da rianodina, diminui&#231;&#227;o da atividade da calsequestrina e calmodulina quinase, redu&#231;&#227;o na fosforila&#231;&#227;o da fosfolambam e redu&#231;&#227;o na atividade da SERCA-2<sup>9</sup>.</p>
    <p>
      <bold>Altera&#231;&#245;es da via beta-adren&#233;rgica</bold>
    </p>
    <p>A intera&#231;&#227;o das catecolaminas com o seu receptor, seguida da convers&#227;o do est&#237;mulo extracelular em resposta intracelular, &#233; denominada via beta-adren&#233;rgica<sup>10</sup>. O est&#237;mulo extracelular age sobre os receptores &#946;1 e &#946;2 que, mediado por prote&#237;na reguladora (prote&#237;na G) interage com o efetor, ativando ou inibindo a produ&#231;&#227;o de 3'5'monofosfato c&#237;clico de adenosina (AMPc) e de quinases. A atividade da adenil ciclase &#233; modulada por duas prote&#237;nas G: a Gs, com capacidade de estimular a ativa&#231;&#227;o da adenil ciclase e a Gi, que &#233; capaz de inibir essa ativa&#231;&#227;o. A ativa&#231;&#227;o da prote&#237;na Gs e do complexo AMPc/quinase promove aumento do c&#225;lcio citos&#243;lico, resultando em efeito inotr&#243;pico positivo. </p>
    <p> Em condi&#231;&#245;es patol&#243;gicas, em que ocorre remodela&#231;&#227;o, foram identificadas diversas altera&#231;&#245;es na via beta-adren&#233;rgica: diminui&#231;&#227;o da concentra&#231;&#227;o de receptores &#946;1, aumento da concentra&#231;&#227;o de receptores &#946;2, diminui&#231;&#227;o dos n&#237;veis de prote&#237;na Gs, aumento dos n&#237;veis de prote&#237;na Gi e redu&#231;&#227;o da atividade da adenil ciclase. Portanto, a exemplo do que ocorre com o tr&#226;nsito de c&#225;lcio, a via beta-adren&#233;rgica provavelmente desempenha papel cr&#237;tico na deteriora&#231;&#227;o da fun&#231;&#227;o card&#237;aca no cora&#231;&#227;o remodelado<sup>10</sup>. </p>
    <p>
      <bold>Altera&#231;&#245;es das prote&#237;nas contr&#225;teis</bold>
    </p>
    <p>O processo de remodela&#231;&#227;o ventricular caracteriza-se por altera&#231;&#245;es na miosina, a principal prote&#237;na contr&#225;til, composta de um par de cadeias pesadas (&#945; e &#946;) e dois pares de cadeias leves. Dependendo da composi&#231;&#227;o das cadeias, podemos identificar tr&#234;s isoenzimas (V1, V2 e V3) no mioc&#225;rdio de diferentes esp&#233;cies. Essas isoenzimas possuem os mesmos pares de cadeias leves, variando apenas em rela&#231;&#227;o &#224; composi&#231;&#227;o das cadeias pesadas (&#945;&#945; nas V1, &#945;&#946; nas V2 e &#946;&#946; nas V3). A capacidade ATP&#225;sica da miosina depende de s&#237;tios ativos localizados nas cadeias pesadas, e a fra&#231;&#227;o a possui maior capacidade ATP&#225;sica. Portanto, a composi&#231;&#227;o das isoenzimas determina a capacidade contr&#225;til do mi&#243;cito. Durante a remodela&#231;&#227;o, al&#233;m de haver predom&#237;nio da forma fetal das cadeias leves da miosina, usualmente ocorre aumento da isoforma V3, acompanhado de diminui&#231;&#227;o da isoforma V1<sup>8</sup>. </p>
    <p>
      <bold>Morte celular</bold>
    </p>
    <p>Podemos identificar tr&#234;s mecanismos de morte do mi&#243;cito: apoptose, ou morte celular programada, autofagia e necrose. A participa&#231;&#227;o dos tr&#234;s diferentes mecanismos de morte celular na deteriora&#231;&#227;o da fun&#231;&#227;o card&#237;aca vem sendo estudada em diversos modelos<sup>11</sup>. No entanto, a exata participa&#231;&#227;o ou contribui&#231;&#227;o dos diferentes mecanismos de morte celular, no processo de remodela&#231;&#227;o e disfun&#231;&#227;o ventricular, ainda &#233; controversa. A despeito desse fato, aceita-se que a perda progressiva de mi&#243;citos esteja presente em v&#225;rios modelos de remodela&#231;&#227;o ventricular e pode participar da deteriora&#231;&#227;o da fun&#231;&#227;o, ap&#243;s o IAM<sup>12</sup>. </p>
    <p>
      <bold>Fibrose</bold>
    </p>
    <p>Os mi&#243;citos representam apenas 30% do n&#250;mero total de c&#233;lulas mioc&#225;rdicas. Circundando e interligando todas essas estruturas h&#225; uma complexa e organizada rede de col&#225;geno. As fibras de col&#225;geno encontradas no interst&#237;cio s&#227;o predominantemente dos tipos I e III (95% do col&#225;geno total). As principais fun&#231;&#245;es dessa rede s&#227;o: regular a apoptose, resistir a deforma&#231;&#245;es patol&#243;gicas, manter o alinhamento das estruturas e regular a distensibilidade card&#237;aca e a transmiss&#227;o de for&#231;a, durante o encurtamento da fibra card&#237;aca. O tecido col&#225;geno, portanto, &#233; um importante modulador tanto da fun&#231;&#227;o card&#237;aca diast&#243;lica quanto da fun&#231;&#227;o sist&#243;lica<sup>13</sup>. </p>
    <p>Existe ampla documenta&#231;&#227;o de que, ap&#243;s o IAM, h&#225; ac&#250;mulo de col&#225;geno (fibrose) nas &#225;reas remotas ao infarto. Nessa condi&#231;&#227;o, a fibrose est&#225; associada &#224; deteriora&#231;&#227;o da fun&#231;&#227;o ventricular<sup>13</sup>.</p>
    <p>
      <bold>Altera&#231;&#245;es das metaloproteases</bold>
    </p>
    <p>Usualmente, as fibras col&#225;genas s&#227;o firmemente justapostas, com fortes liga&#231;&#245;es qu&#237;micas e resistentes &#224; degrada&#231;&#227;o causada pela maioria das proteases. Algumas enzimas, entretanto, t&#234;m atividade colagenol&#237;tica, entre as quais se destacam as metaloproteases. Essas enzimas encontram-se em formas inativas (proenzima latente), podendo ser ativadas por uma s&#233;rie de est&#237;mulos: mec&#226;nicos, isqu&#234;micos, angiotensina II, endotelina 1, catecolaminas, fator de necrose tumoral, interleucina 1, entre outros<sup>14</sup>. </p>
    <p>A quebra da rede de col&#225;geno interfibrilar pode ter in&#250;meras conseq&#252;&#234;ncias, tanto na arquitetura quanto na fun&#231;&#227;o ventricular. Por exemplo, em ratos com infarto agudo do mioc&#225;rdio, o aumento da atividade das metaloproteases foi acompanhado de dilata&#231;&#227;o ventricular progressiva. Da mesma forma, a inibi&#231;&#227;o farmacol&#243;gica das metaloproteases, em animais com IAM, atenuou o processo de remodela&#231;&#227;o, com conseq&#252;ente preserva&#231;&#227;o funcional<sup>15,16</sup>. Os dados dispon&#237;veis, portanto, sugerem participa&#231;&#227;o importante das metaloproteases na remodela&#231;&#227;o e disfun&#231;&#227;o ventricular secund&#225;ria ao IAM. </p>
    <p>
      <bold>Aumento do estresse oxidativo</bold>
    </p>
    <p>J&#225; est&#225; bem documentado que o IAM resulta em aumento de estresse oxidativo. S&#227;o v&#225;rias as proced&#234;ncias das esp&#233;cies reativas de oxig&#234;nio, dentre as quais destacam-se: transportadores de el&#233;trons mitocondriais, sistema NADPH oxidase, atividade da cicloxigenase, citocromo P450, glicose oxidase, xantina oxidase, lipoxigenase e degrada&#231;&#227;o das catecolaminas<sup>17</sup>. As esp&#233;cies reativas ativariam diversos sinalizadores celulares que, na fase aguda, participariam do processo inflamat&#243;rio e da cicatriza&#231;&#227;o da regi&#227;o infartada. Cronicamente, entretanto, o estresse oxidativo induziria remodela&#231;&#227;o por resultar em disfun&#231;&#227;o mitocondrial, ativa&#231;&#227;o das metaloproteases, fibrose, hipertrofia e morte celular<sup>18-20</sup>.</p>
    <p>
      <bold>D&#233;ficit energ&#233;tico</bold>
    </p>
    <p>Outro fator potencialmente respons&#225;vel pela altera&#231;&#227;o da fun&#231;&#227;o card&#237;aca no cora&#231;&#227;o remodelado &#233; o d&#233;ficit energ&#233;tico, que resulta do desequil&#237;brio entre oferta e consumo de oxig&#234;nio. Em condi&#231;&#245;es normais, os &#225;cidos graxos livres (AGL) s&#227;o o principal substrato energ&#233;tico do cora&#231;&#227;o, com participa&#231;&#227;o variando de 60% a 90%. Por meio de processo de &#946;-oxida&#231;&#227;o, metab&#243;litos dos AGL participam da produ&#231;&#227;o de ATP nos transportadores de el&#233;trons na mitoc&#244;ndria. Ap&#243;s a produ&#231;&#227;o, a energia produzida &#233; estocada e transportada na forma de fosfocreatina. J&#225; foram identificadas diversas altera&#231;&#245;es do metabolismo energ&#233;tico na remodela&#231;&#227;o, que se manifestam com diminui&#231;&#227;o da produ&#231;&#227;o de energia: diminui&#231;&#227;o na utiliza&#231;&#227;o dos AGL e aumento da utiliza&#231;&#227;o de glicose como substrato energ&#233;tico, diminui&#231;&#227;o da &#946;-oxida&#231;&#227;o e altera&#231;&#245;es funcionais mitocondriais. Essas altera&#231;&#245;es est&#227;o associadas &#224; diminui&#231;&#227;o dos n&#237;veis de fosfocreatina que, como dito anteriormente, representa a forma na qual o ATP &#233; estocado<sup>21,22</sup>. Como conseq&#252;&#234;ncia, todas as prote&#237;nas mioc&#225;rdicas com capacidade ATP&#225;sica, como as da cadeia pesada da miosina e as respons&#225;veis pela capta&#231;&#227;o de c&#225;lcio pelo ret&#237;culo sarcoplasm&#225;tico, podem apresentar d&#233;ficits em suas fun&#231;&#245;es, com deteriora&#231;&#227;o tanto da fun&#231;&#227;o card&#237;aca sist&#243;lica quanto da dist&#243;lica<sup>5</sup>.</p>
    <p>
      <bold>Sistema renina-angiotensina-aldosterona</bold>
    </p>
    <p>Na fisiopatologia do processo de remodela&#231;&#227;o p&#243;s-IAM, merece destaque a participa&#231;&#227;o do sistema renina-angiotensina-aldosterona<sup>4,5,23,24</sup>. A ativa&#231;&#227;o desse sistema estimula vias de sinaliza&#231;&#227;o intracelulares com conseq&#252;ente aumento da s&#237;ntese prot&#233;ica em mi&#243;citos e fibroblastos causando hipertrofia celular e fibrose. Outros efeitos seriam o aumento da permeabilidade dos vasos, ativa&#231;&#227;o de fatores de crescimento, ativa&#231;&#227;o das metaloproteases, sobrecarga hemodin&#226;mica por vasoconstri&#231;&#227;o e reten&#231;&#227;o h&#237;drica, aumento do estresse oxidativo e efeito citot&#243;xico direto, levando &#224; morte celular por necrose ou apoptose. Assim, o bloqueio do sistema renina-angiotensina &#233; uma estrat&#233;gia atraente para o tratamento da remodela&#231;&#227;o p&#243;s-infarto, como se ver&#225; adiante.</p>
    <p>
      <bold>Outras altera&#231;&#245;es</bold>
    </p>
    <p>Altera&#231;&#245;es das prote&#237;nas de membrana, da matriz e do citoesqueleto tamb&#233;m podem acompanhar o processo de remodela&#231;&#227;o. Existem relatos de que no cora&#231;&#227;o remodelado, altera&#231;&#245;es da tubulina, desmina, titina, integrinas, ADAM (<italic>A Desintegrin And Metaloproteinase</italic>), metaloproteases de membrana, trombospondina 2, osteopontina e tenascina C est&#227;o relacionadas &#224; disfun&#231;&#227;o ventricular<sup>25-27</sup>. Portanto, altera&#231;&#245;es das prote&#237;nas do citoesqueleto, da membrana e da matriz celular poderiam participar da fisiopatologia da disfun&#231;&#227;o ventricular, que acompanha a remodela&#231;&#227;o ap&#243;s o IAM.</p>
    <p>Adicionalmente, um dos principais mecanismos pelos quais o mi&#243;cito se adapta a um determinado est&#237;mulo &#233; o processo de hipertrofia. Nos &#250;ltimos anos, estudos experimentais, ap&#243;s o infarto, verificaram que a contratilidade mioc&#225;rdica dos animais infartados n&#227;o apresentava altera&#231;&#245;es. Esse fen&#244;meno ocorria apesar da presen&#231;a de dilata&#231;&#227;o ventricular esquerda, acompanhada de sinais de disfun&#231;&#227;o e de insufici&#234;ncia card&#237;aca, como congest&#227;o pulmonar. Os autores conclu&#237;ram que, apesar da capacidade intr&#237;nseca do m&#250;sculo na gera&#231;&#227;o de for&#231;a ser igual entre os animais com e sem infarto, os ratos infartados apresentavam fun&#231;&#227;o ventricular deprimida. Desse modo, o pr&#243;prio processo de remodela&#231;&#227;o, pelas mudan&#231;as geom&#233;tricas ocorridas, poderia comprometer a fun&#231;&#227;o global do cora&#231;&#227;o<sup>28,29</sup>.</p>
    <p>Pelo exposto, a remodela&#231;&#227;o ventricular envolve uma s&#233;rie de altera&#231;&#245;es morfol&#243;gicas, em resposta a determinado est&#237;mulo ou inj&#250;ria. Inicialmente, esse processo pode ser adaptativo, mas, em longo prazo, uma das conseq&#252;&#234;ncias da remodela&#231;&#227;o seria o aparecimento de progressiva disfun&#231;&#227;o ventricular. Os mecanismos respons&#225;veis pela deteriora&#231;&#227;o funcional n&#227;o est&#227;o completamente esclarecidos, mas podem incluir altera&#231;&#245;es gen&#233;ticas, estruturais, bioqu&#237;micas e energ&#233;ticas.</p>
    <p>
      <bold>Fatores determinantes da remodela&#231;&#227;o ventricular</bold>
    </p>
    <p>O processo de remodela&#231;&#227;o ventricular n&#227;o ocorre de maneira homog&#234;nea ap&#243;s o IAM. A preval&#234;ncia e a intensidade desse processo s&#227;o influenciadas por quatro fatores:</p>
    <p>
      <bold>1) Caracter&#237;sticas morfol&#243;gicas do infarto</bold>
    </p>
    <p>Apesar de a remodela&#231;&#227;o incidir em diferentes tamanhos de les&#227;o isqu&#234;mica, sua predomin&#226;ncia &#233; observada em infartos de maior tamanho. Da mesma maneira, parece haver, como pr&#233;-requisito, tamanho m&#237;nimo de les&#227;o (16%-20%) para que ocorra a remodela&#231;&#227;o. Outro fator refere-se ao fato de que, em raz&#227;o da grande curvatura ventricular e do afilamento da parede &#226;ntero-apical, a remodela&#231;&#227;o ocorre mais freq&#252;entemente nessa regi&#227;o, tipicamente em infartos transmurais<sup>3,30,31</sup>. </p>
    <p>
      <bold>2) Caracter&#237;sticas da cicatriza&#231;&#227;o</bold>
    </p>
    <p>Nas fases iniciais p&#243;s-IAM ocorre aumento importante do col&#225;geno na zona infartada. Inicialmente, h&#225; aumento do col&#225;geno tipo III. Esse, reconhecidamente, apresenta menor resist&#234;ncia &#224; deforma&#231;&#227;o que o col&#225;geno tipo I, mais duro, que &#233; predominante em cora&#231;&#245;es normais. Com o passar do tempo, h&#225; decr&#233;scimo do col&#225;geno tipo III e eleva&#231;&#227;o do tipo I. Admite-se que o col&#225;geno neoformado seja menos rijo do que o col&#225;geno maduro. Esse fato, associado &#224; predomin&#226;ncia do col&#225;geno tipo III, determina per&#237;odo de potencial vulnerabilidade da cicatriz &#224;s eventuais for&#231;as deformantes. Portanto, a cicatriz do IAM &#233; processo din&#226;mico e sens&#237;vel a interven&#231;&#245;es<sup>32</sup>. Como exemplo, a administra&#231;&#227;o de AINH ou corticoster&#243;ides resultou em cicatriza&#231;&#227;o mais lenta, tornando a regi&#227;o mais suscept&#237;vel a deforma&#231;&#245;es, com acentua&#231;&#227;o da expans&#227;o ventricular<sup>3</sup>. </p>
    <p>
      <bold>3) Estresse hemodi&#226;mico</bold>
    </p>
    <p>Em rela&#231;&#227;o ao estresse hemodin&#226;mico, sabe-se que, durante a fase aguda do infarto, &#233; comum ocorrerem flutua&#231;&#245;es das condi&#231;&#245;es de carga com as quais o cora&#231;&#227;o trabalha. J&#225; est&#225; bem documentado que sobrecargas card&#237;acas interferem no processo de remodela&#231;&#227;o<sup>3-5</sup>. Por exemplo, em estudos experimentais, manobras como a constri&#231;&#227;o da aorta, infus&#227;o de metoxamina e exerc&#237;cio f&#237;sico precoce resultaram em maior dilata&#231;&#227;o ventricular em compara&#231;&#227;o aos animais controle. Do mesmo modo, seres humanos com hipertens&#227;o arterial apresentaram intensifica&#231;&#227;o do processo de remodela&#231;&#227;o<sup>3</sup>.</p>
    <p>
      <bold>4) Moduladores</bold>
    </p>
    <p>O infarto se caracteriza, em praticamente todos os casos, pelo aumento dos n&#237;veis de diversos moduladores, como angiotensina II, endotelina 1, catecolaminas, fator de necrose tumoral, interleucinas 1 e 6, fator de crescimento transformador beta-1 e fator de crescimento s&#237;mile-insulina 1. Aceita-se que esse aumento tenha participa&#231;&#227;o fisiopatol&#243;gica, j&#225; que os diferentes moduladores regulam os eventos iniciais do infarto, como rea&#231;&#227;o inflamat&#243;ria e processo de cicatriza&#231;&#227;o. Adicionalmente, eles resultam em efeitos hemodin&#226;micos e inotr&#243;picos, que servem como contraposi&#231;&#227;o &#224; perda de tecido contr&#225;til, contribuindo para a estabiliza&#231;&#227;o hemodin&#226;mica dos pacientes. Em situa&#231;&#245;es fisiol&#243;gicas, os n&#237;veis dos moduladores voltam ao normal em aproximadamente uma semana. Em alguns casos, entretanto, os n&#237;veis desses fatores podem permanecer elevados. Modelos experimentais j&#225; determinaram que n&#237;veis aumentados dos moduladores podem tanto desencadear como regular a remodela&#231;&#227;o card&#237;aca<sup>33,34</sup>.</p>
    <p>
      <bold>Hist&#243;ria natural da remodela&#231;&#227;o ventricular</bold>
    </p>
    <p>Ap&#243;s o infarto, cerca de 50% dos pacientes evoluem com algum grau de dilata&#231;&#227;o ventricular esquerda. Desses, 50% dos pacientes evoluem com aumentos progressivos da c&#226;mara ventricular, enquanto 50% permanecem est&#225;veis. Dos pacientes que n&#227;o apresentam dilata&#231;&#227;o na fase aguda, parcela ainda n&#227;o definida de pacientes apresentar&#225; o processo de remodela&#231;&#227;o ap&#243;s semanas, meses ou anos ap&#243;s o insulto isqu&#234;mico<sup>35</sup>.</p>
    <p>
      <bold>Diagn&#243;stico</bold>
    </p>
    <p>O diagn&#243;stico da remodela&#231;&#227;o ap&#243;s o infarto, clinicamente, baseia-se na detec&#231;&#227;o do aumento da cavidade do ventr&#237;culo esquerdo. Para tanto, os m&#233;todos mais utilizados s&#227;o o ecocardiograma, a ventriculografia e a resson&#226;ncia magn&#233;tica. Aceita-se que a resson&#226;ncia magn&#233;tica tem melhor sensibilidade para a detec&#231;&#227;o de altera&#231;&#245;es no di&#226;metro da cavidade ventricular esquerda. No entanto, em raz&#227;o dos custos e exig&#234;ncias t&#233;cnicas, sua aplica&#231;&#227;o cl&#237;nica &#233; ainda limitada. Por esse motivo, na pr&#225;tica cl&#237;nica e mesmo em grandes ensaios cl&#237;nicos, o m&#233;todo mais utilizado para o diagn&#243;stico de remodela&#231;&#227;o &#233; o ecocardiograma<sup>36</sup>. </p>
    <p>Outra forma de diagn&#243;stico, por enquanto usado apenas em modelos experimentais e relatos cl&#237;nicos isolados, baseia-se na detec&#231;&#227;o de marcadores celulares que caracterizam o gen&#243;tipo fetal. Entre esses, podemos citar: altera&#231;&#245;es da cadeia pesada da miosina, com diminui&#231;&#227;o da &#945; e aumento da &#946;-miosina, aumento da &#945;-actina, aumento dos pept&#237;deos natriur&#233;ticos, diminui&#231;&#227;o do GLUT-4 e aumento do GLUT-1, diminui&#231;&#227;o da SERCA-2a e aumento da enzima conversora da angiotensina<sup>3-5,8,37</sup>.</p>
    <p>
      <bold>Diagn&#243;stico diferencial</bold>
    </p>
    <p>O deslizamento de feixes musculares, caracter&#237;sticos da expans&#227;o do infarto, quando realizado de forma abrupta e intensa, pode resultar em dor precordial de vari&#225;vel magnitude. Outro aspecto a ser considerado &#233; que, apesar da expans&#227;o n&#227;o variar a quantidade de tecido necr&#243;tico, o deslizamento das fibras aumenta a superf&#237;cie mioc&#225;rdica infartada. Desse modo, pode ocorrer intensifica&#231;&#227;o do supradesnivelamento do segmento ST nas deriva&#231;&#245;es j&#225; comprometidas ou podem ocorrer altera&#231;&#245;es do segmento ST em deriva&#231;&#245;es inicialmente n&#227;o comprometidas. Adicionalmente, em casos extremos, parcela de sangue pode ficar retida na regi&#227;o expandida durante a s&#237;stole, ocasionando diminui&#231;&#227;o do volume s&#237;st&#243;lico e comprometimento hemodin&#226;mico<sup>38</sup>.</p>
    <p>Por essas raz&#245;es, o principal diagn&#243;stico diferencial da expans&#227;o &#233; a extens&#227;o do infarto (<xref ref-type="table" rid="tab01">tab. 1</xref>). Enquanto a expans&#227;o &#233; evento freq&#252;ente (50%), a extens&#227;o ocorre em menos de 20% dos casos de IAM. A expans&#227;o se manifesta mais freq&#252;entemente nos primeiros dias do infarto, em grandes infartos transmurais da parede anterior, ao passo que a extens&#227;o pode ocorrer em qualquer situa&#231;&#227;o. Entretanto, a principal distin&#231;&#227;o entre as duas complica&#231;&#245;es &#233; que a extens&#227;o, por implicar novos focos de necrose, se acompanha de nova eleva&#231;&#227;o enzim&#225;tica<sup>38</sup>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt01.jpg"/></table-wrap>
    <p>
      <bold>Fatores de predi&#231;&#227;o da remodela&#231;&#227;o</bold>
    </p>
    <p>Como dito anteriormente, v&#225;rios fatores favorecem o aparecimento da remodela&#231;&#227;o, e os mais importantes s&#227;o: infartos grandes, transmurais e anteriores, queda da fra&#231;&#227;o de eje&#231;&#227;o, aus&#234;ncia ou inefic&#225;cia de reperfus&#227;o, fen&#244;meno do no-reflow, reoclus&#227;o coron&#225;ria precoce, presen&#231;a de hipertens&#227;o arterial e uso de AINH e corticoester&#243;ide na fase aguda do IAM (<xref ref-type="table" rid="tab02">tab. 2</xref>)<sup>3,4,35</sup>. Recentemente, dados experimentais sugerem que o tabagismo poderia intensificar a remodela&#231;&#227;o p&#243;s-IAM<sup>39</sup>. Do mesmo modo, recente estudo cl&#237;nico sugere que altos valores basais de glicemia tamb&#233;m podem predizer remodela&#231;&#227;o<sup>40</sup>. Infartos pequenos, infartos subendoc&#225;rdicos, infartos inferiores, reperfus&#227;o presente e mantida, avaliada pela resolu&#231;&#227;o do segmento ST, microcircula&#231;&#227;o perme&#225;vel, angina pr&#233;via, aus&#234;ncia de co-morbidades e certas medica&#231;&#245;es s&#227;o fatores que previnem o aparecimento de remodela&#231;&#227;o<sup>3,4,35,41-43</sup>.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt02.jpg"/></table-wrap>
    <p>
      <bold>Aspectos controversos sobre remodela&#231;&#227;o p&#243;s-IAM</bold>
    </p>
    <p>Apesar de o tema remodela&#231;&#227;o ser um dos mais estudados dos &#250;ltimos anos, pela sua relev&#226;ncia, v&#225;rios aspectos permanecem controversos. </p>
    <p>Em primeiro lugar, o infarto se caracteriza por morte de tecido card&#237;aco, que &#233; substitu&#237;do por tecido de cicatriza&#231;&#227;o. Assim, conceitualmente, todo cora&#231;&#227;o infartado muda sua composi&#231;&#227;o, ou seja, sofre remodela&#231;&#227;o. Do ponto de vista cl&#237;nico, entretanto, como j&#225; discutido, o termo remodela&#231;&#227;o, ap&#243;s o infarto, &#233; comumente utilizado para assinalar o aumento patol&#243;gico da cavidade ventricular. </p>
    <p>Outro aspecto a ser considerado &#233; que, usualmente, o termo remodela&#231;&#227;o &#233; utilizado para caracterizar adapta&#231;&#245;es patol&#243;gicas. No entanto, nem sempre esse conceito se aplica. Por exemplo, como discutido anteriormente, 50% dos pacientes ap&#243;s o infarto evoluem com aumento da cavidade ventricular na fase aguda. Apenas metade desses pacientes, no entanto, apresenta aumento progressivo da cavidade e piora da fun&#231;&#227;o ventricular. Os outros pacientes permanecem est&#225;veis, tanto morfologicamente quanto em rela&#231;&#227;o &#224; fun&#231;&#227;o. Esse fato sugere que, nesses pacientes, o aumento da cavidade pode ser adaptativo e sem conseq&#252;&#234;ncias delet&#233;rias. Adicionalmente, existem diversos modelos de animais transg&#234;nicos que apresentam hipertrofia e dilata&#231;&#227;o ventricular em resposta a diferentes sobrecargas, mas sem sinais de disfun&#231;&#227;o ventricular ou comprometimento da sobrevida<sup>44</sup>. As evid&#234;ncias acumuladas at&#233; o presente, portanto, sugerem que, em determinadas situa&#231;&#245;es, as altera&#231;&#245;es card&#237;acas caracter&#237;sticas da remodela&#231;&#227;o podem ser adaptativas e contribu&#237;rem para a manuten&#231;&#227;o da fun&#231;&#227;o ventricular, em resposta a determinados est&#237;mulos (remodela&#231;&#227;o adaptativa ou fisiol&#243;gica). Adicionalmente, aceita-se que esse processo adaptativo seria modulado por vias de sinaliza&#231;&#227;o celulares diferentes (via da fosfatidil inositol 3-quinase) das vias envolvidas nas remodela&#231;&#245;es patol&#243;gicas (fosfolipase C, prote&#237;na quinase C e calcineurina)<sup>45-47</sup>.</p>
    <p>Finalmente, &#233; importante ressaltar que o processo de remodela&#231;&#227;o &#233; extremamente complexo, implicando em altera&#231;&#245;es gen&#233;ticas, celulares e moleculares. As altera&#231;&#245;es morfol&#243;gicas, como o aumento da cavidade p&#243;s-infarto, s&#227;o apenas a forma pela qual os cl&#237;nicos conseguem diagnosticar e estratificar o fen&#244;meno. Assim, at&#233; recentemente, estrat&#233;gias visando &#224; revers&#227;o da remodela&#231;&#227;o tinham como foco apenas a regress&#227;o das altera&#231;&#245;es morfol&#243;gicas. Por essa raz&#227;o, at&#233; o momento existem d&#250;vidas se a regress&#227;o das altera&#231;&#245;es morfol&#243;gicas se acompanha de revers&#227;o das altera&#231;&#245;es gen&#233;ticas, bioqu&#237;micas e celulares. Dados mais recentes sugerem, no entanto, que com algumas interven&#231;&#245;es em pacientes com insufici&#234;ncia card&#237;aca, a redu&#231;&#227;o da espessura da parede e do volume da cavidade do ventr&#237;culo esquerdo foi acompanhada de: diminui&#231;&#227;o do tamanho do mi&#243;cito, recupera&#231;&#227;o do tr&#226;nsito de c&#225;lcio, melhora do citoesqueleto e da via &#946;-adren&#233;rgica, redu&#231;&#227;o da quantidade de col&#225;geno e, possivelmente, altera&#231;&#245;es das vias intracelulares respons&#225;veis pela remodela&#231;&#227;o<sup>48</sup>. A revers&#227;o cl&#237;nica da remodela&#231;&#227;o, portanto, parece ser evento real e &#233; acompanhada de revers&#227;o das altera&#231;&#245;es fisiopatol&#243;gicas que modulam esse processo.</p>
    <p>
      <bold>Preven&#231;&#227;o - atenua&#231;&#227;o - revers&#227;o da remodela&#231;&#227;o</bold>
    </p>
    <p>Por atenuar tanto o tamanho do infarto quanto a transmuralidade, a reperfus&#227;o mioc&#225;rdica eficaz e duradoura &#233; a principal medida preventiva da remodela&#231;&#227;o. Por n&#227;o influenciar as caracter&#237;sticas da cicatriza&#231;&#227;o, o AAS &#233; a medica&#231;&#227;o antiinflamat&#243;ria de escolha na fase aguda do IAM. Outra medida &#233; a diminui&#231;&#227;o do estresse parietal do ventr&#237;culo esquerdo; assim, devemos evitar aumentos press&#243;ricos na fase aguda do IAM.</p>
    <p>Em rela&#231;&#227;o &#224;s medica&#231;&#245;es espec&#237;ficas, estudos experimentais mostraram que o uso precoce dos inibidores da enzima conversora da angiotensina (IECA) atenuava a remodela&#231;&#227;o<sup>2,49</sup>. Essas observa&#231;&#245;es foram confirmadas em estudos cl&#237;nicos<sup>50,51</sup>. Do mesmo modo, no modelo do rato, o uso precoce de antagonistas de receptores AT1 da angiotensina II atenuou a remodela&#231;&#227;o e reduziu a mortalidade p&#243;s-IAM<sup>52</sup>. Posteriormente, estudos cl&#237;nicos n&#227;o encontraram diferen&#231;a nas a&#231;&#245;es dos ARAII em rela&#231;&#227;o aos IECA, ap&#243;s o infarto<sup>53</sup>. Apesar de, em pacientes com disfun&#231;&#227;o ventricular, com fra&#231;&#227;o de eje&#231;&#227;o &lt;40%, o uso de betabloqueadores e antagonistas da aldosterona tamb&#233;m ser acompanhado de melhor progn&#243;stico<sup>54,55</sup>, o efeito dessas medica&#231;&#245;es em pacientes sem disfun&#231;&#227;o ventricular, ap&#243;s o infarto, ainda n&#227;o s&#227;o conhecidos. Finalmente, devemos considerar que a revasculariza&#231;&#227;o em pacientes com mioc&#225;rdio hibernante pode estar associada a menor remodela&#231;&#227;o<sup>56,57</sup>. Outras abordagens terap&#234;uticas para preven&#231;&#227;o, atenua&#231;&#227;o ou revers&#227;o da remodela&#231;&#227;o ap&#243;s o infarto, como o uso de regenera&#231;&#227;o celular, antagonistas da vasopressina, pept&#237;deos natriur&#233;ticos, sincroniza&#231;&#227;o ventricular, dispositivos mec&#226;nicos, nitratos e estatinas, ainda precisam ser confirmadas em grandes estudos cl&#237;nicos.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A remodela&#231;&#227;o ventricular &#233; evento relativamente comum, p&#243;s-IAM. A relev&#226;ncia da remodela&#231;&#227;o est&#225; associada ao fato de que, al&#233;m de resultar em maior preval&#234;ncia de ruptura card&#237;aca, arritmias e forma&#231;&#227;o de aneurismas, esse processo pode modular o aparecimento e a progress&#227;o da disfun&#231;&#227;o ventricular, da insufici&#234;ncia card&#237;aca e de morte ap&#243;s o infarto. Outro fato a ser considerado &#233; que esse processo n&#227;o ocorre de forma homog&#234;nea nos pacientes com IAM. Dessa forma, pacientes com remodela&#231;&#227;o j&#225; diagnosticada, ou com alto risco para desenvolv&#234;-la, devem ser tratados de forma agressiva, com a inten&#231;&#227;o de prevenir, atenuar ou mesmo reverter esse processo.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Leonardo Ant&#244;nio Mamede Zornoff </p>
        <p> Faculdade de Medicina de Botucatu / Departamento de Cl&#237;nica M&#233;dica </p>
        <p> Distrito de Rubi&#227;o Jr, s/n </p>
        <p> Botucatu, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="lzornoff@cardiol.br">lzornoff@cardiol.br</email>, </p>
        <p>
          <email xlink:href="lzornoff@fmb.unesp.br">lzornoff@fmb.unesp.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo enviado em 14/08/2007; revisado enviado em 14/01/2008; aceito em 26/02/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Hockman JS, Bulkley BH. Expansion of acute    myocardial infarction: an experimental study. Circulation. 1982; 65: 1446-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Expansion of acute myocardial infarction: an experimental study</article-title>
          <source>Circulation</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>1446</fpage>
          <lpage>50</lpage>
          <volume>65</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hockman</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Bulkley</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Pfeffer JM, Pfeffer MA, Braunwald E. Influence    of chronic captopril therapy on the infarcted left ventricle of the rat. Circ    Res. 1985; 57: 84-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influence of chronic captopril therapy on the infarcted left ventricle of the rat</article-title>
          <source>Circ Res</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>84</fpage>
          <lpage>95</lpage>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Pfeffer MA, Braunwald E. Ventricular remodeling    after myocardial infarction: experimental observations and clinical implications.    Circulation. 1990; 81: 1161-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventricular remodeling after myocardial infarction: experimental observations and clinical implications</article-title>
          <source>Circulation</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1161</fpage>
          <lpage>72</lpage>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts    and clinical implications: a consensus paper from an international forum on    cardiac remodeling. J Am Coll Cardiol. 2000; 35: 569-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>569</fpage>
          <lpage>82</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Francis GS. Pathophysiology of chronic heart    failure. Am J Med. 2001; 110: 37S-46S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathophysiology of chronic heart failure</article-title>
          <source>Am J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>37S</fpage>
          <lpage>46S</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Matsubara BB, Zornoff LAM. Matriz col&#225;gena    intersticial e sua rela&#231;&#227;o com a expans&#227;o mioc&#225;rdica    no infarto agudo. Arq Bras Cardiol. 1995; 64: 559-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Matriz col&#225;gena intersticial e sua rela&#231;&#227;o com a expans&#227;o mioc&#225;rdica no infarto agudo</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>559</fpage>
          <lpage>63</lpage>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Zornoff LAM, Spadaro J. Remodela&#231;&#227;o    ventricular ap&#243;s infarto agudo do mioc&#225;rdio: conceitos, fisiopatologia    e abordagem terap&#234;utica. Arq Bras Cardiol. 1997; 68: 453-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Remodela&#231;&#227;o ventricular ap&#243;s infarto agudo do mioc&#225;rdio: conceitos, fisiopatologia e abordagem terap&#234;utica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>453</fpage>
          <lpage>60</lpage>
          <volume>68</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Swynghedauw B. Molecular mechanisms of myocardial    remodeling. Physiol Rev. 1999; 79: 215-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular mechanisms of myocardial remodeling</article-title>
          <source>Physiol Rev</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>215</fpage>
          <lpage>62</lpage>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Swynghedauw</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Hasenfuus G, Meyer M, Schillinger W, Preus    M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic    Res Cardiol. 1997; 92: 87-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Calcium handling proteins in the failing human heart</article-title>
          <source>Basic Res Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>87</fpage>
          <lpage>93</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hasenfuus</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schillinger</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Preus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pieske</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Just</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Barros RA, Okoshi MP, Cicogna AC. Via beta-adren&#233;rgica    em cora&#231;&#245;es normais e hipertrofiados. Arq Bras Cardiol. 1999;    72: 641-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Via beta-adren&#233;rgica em cora&#231;&#245;es normais e hipertrofiados</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>641</fpage>
          <lpage>8</lpage>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barros</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Kunapuli S, Rosanio S, Schwarz ER. How do    cardiomiocytes die? Apoptosis and autofagic cell death in cardiac myocytes.    J Card Fail. 2006; 12: 381-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>How do cardiomiocytes die?: Apoptosis and autofagic cell death in cardiac myocytes</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>381</fpage>
          <lpage>8</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kunapuli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosanio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Takemura G, Fujiwara H. Role of apoptosis    in remodeling after myocardial infarction. Pharmacol Ther. 2004; 104: 1-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of apoptosis in remodeling after myocardial infarction</article-title>
          <source>Pharmacol Ther</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Takemura</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Weber KT, Sun Y, Guntaka RV. Rebuilding and    remodeling following myocardial infarction: the good, the bad, and the ugly    of tissue repair. Dialogues in Cardiovascular Medicine. 1999; 4: 3-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Rebuilding and remodeling following myocardial infarction: the good, the bad, and the ugly of tissue repair</article-title>
          <source>Dialogues in Cardiovascular Medicine</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>3</fpage>
          <lpage>19</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Guntaka</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Cleutjens JPM. The role of matrix metalloproteinases    in heart disease. Cardiovasc Res. 1996; 816-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of matrix metalloproteinases in heart disease</article-title>
          <source>Cardiovasc Res.</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>816</fpage>
          <lpage>21</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Cleutjens</surname>
              <given-names>JPM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Spinale FG. Matrix metalloproteinases: regulation    and dysregulation in the failing heart. Circ Res. 2002; 90: 520-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Matrix metalloproteinases: regulation and dysregulation in the failing heart</article-title>
          <source>Circ Res</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>520</fpage>
          <lpage>30</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spinale</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Rohde LE, Ducharme A, Arroyo LH, Aikawa M,    Houck WC, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates    early left ventricular enlargement after myocardial infarction in mice. Circulation.    1999; 99: 3063-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after myocardial infarction in mice</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>3063</fpage>
          <lpage>70</lpage>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Ducharme</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arroyo</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Aikawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Houck</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Lopez-Anaya</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Takimoto E, Kass DA. Role of oxidative stress    in cardiac hypertrophy and remodeling. Hypertension. 2007; 49: 241-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of oxidative stress in cardiac hypertrophy and remodeling</article-title>
          <source>Hypertension</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>241</fpage>
          <lpage>8</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Takimoto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kass</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Grieve DJ, Byrne JA, Cave AC, Shah AM. Role    of oxidative stress in cardiac remodeling after myocardial infarction. Heart    Lung Circ. 2004; 13: 132-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of oxidative stress in cardiac remodeling after myocardial infarction</article-title>
          <source>Heart Lung Circ</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>132</fpage>
          <lpage>8</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grieve</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Byrne</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Cave</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Giordano FJ. Oxygen, oxidative stress, hypoxia,    and heart failure. J Clin Invest. 2005; 115: 500-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oxygen, oxidative stress, hypoxia, and heart failure</article-title>
          <source>J Clin Invest</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>500</fpage>
          <lpage>8</lpage>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Giordano</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Sawyer DB, Siwik DA, Xiao J, Pimentel DR,    Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and    failure. J Mol Cell Cardiol. 2002; 34: 379-88.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of oxidative stress in myocardial hypertrophy and failure</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>379</fpage>
          <lpage>88</lpage>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sawyer</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Siwik</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Colucci</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Neubauer SN. The failing heart  an engine    out of fuel. N Engl J Med. 2007; 356: 1140-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The failing heart - an engine out of fuel</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1140</fpage>
          <lpage>51</lpage>
          <volume>356</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Neubauer</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Ashrafian H, Frenneaux MP, Opie LH. Metabolic    mechanisms in heart failure. Circulation. 2007; 116: 434-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic mechanisms in heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>434</fpage>
          <lpage>48</lpage>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ashrafian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Frenneaux</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Opie</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Sadoshima J, Izumo S. Molecular characterization    of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of    cardiac fibloblasts. Critical role of AT1 receptor subtype. Cir Res. 1993; 73:    413-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibloblasts: Critical role of AT1 receptor subtype</article-title>
          <source>Cir Res</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>413</fpage>
          <lpage>23</lpage>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sadoshima</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Izumo</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Udelson JE, Patten RD, Konstam MA. New concepts    in post-infarction ventricular remodeling. Rev Cardiovasc Med. 2003; 4 (Suppl    3): S3-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New concepts in post-infarction ventricular remodeling</article-title>
          <source>Rev Cardiovasc Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>S3</fpage>
          <lpage>12</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Udelson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Patten</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Hein S, Kostin S, Heling A, Maeno Y, Schaper    J. The role of the cytoskeleton in the heart failure. Cardiovasc Res. 2000;    45: 273-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of the cytoskeleton in the heart failure</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>273</fpage>
          <lpage>8</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kostin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Heling</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maeno</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Schaper</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Manso AM, Elsherif L, Kang SM, Ross RS. Integrins,    membrane-type matrix metalloproteinases and ADAMs: potential implications for    cardiac remodeling. Cardiovasc Res. 2006; 69: 574-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>574</fpage>
          <lpage>84</lpage>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Manso</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Elsherif</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Schellings MW, Pinto YM, Heymans S. Matricellular    proteins in the heart: possible role during stress and remodeling. Cardiovasc    Res. 2004; 64: 24-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Matricellular proteins in the heart: possible role during stress and remodeling</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>24</fpage>
          <lpage>31</lpage>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schellings</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Heymans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Anand IS. Ventricular remodeling without    cellular contractile dysfunction. J Card Fail. 2002; 8 (Suppl): S401-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventricular remodeling without cellular contractile dysfunction</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>S401</fpage>
          <lpage>8</lpage>
          <issue>Suppl</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Peron AP, Saraiva RM, Antonio EL, Tucci PJ.    Mechanical function is normal in remanent myocardium during the healing period    of myocardial infarction--despite congestive heart failure. Arq Bras Cardiol.    2006; 86: 105-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanical function is normal in remanent myocardium during the healing period of myocardial infarction--despite congestive heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>105</fpage>
          <lpage>12</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Peron</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Saraiva</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Antonio</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Tucci</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Eaton LW, Bulkley BH. Expansion of acute    myocardial infarction: its relationship to infarct morphology in a canine model.    Circ Res. 1981; 49: 80-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Expansion of acute myocardial infarction: its relationship to infarct morphology in a canine model</article-title>
          <source>Circ Res</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>80</fpage>
          <lpage>8</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Eaton</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Bulkley</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher    PJ, Spadaro J, Kloner RA, et al. Myocardial infarct size and ventricular function    in rats. Circ Res. 1979; 44: 503-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial infarct size and ventricular function in rats</article-title>
          <source>Circ Res</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>503</fpage>
          <lpage>12</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Fishbein</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kloner</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Whittaker P. Unravelling the mysteries of    collegen and cicatriz after myocardial infarction. Cardiovasc Res. 1995; 29:    758-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Unravelling the mysteries of collegen and cicatriz after myocardial infarction</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>758</fpage>
          <lpage>62</lpage>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Whittaker</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Rouleau JL, Moy&#233; LA, Champlain J,    Klein M, Bichet D, Parker M, et al. Activation of neurohumoral systems following    acute myocardial infarction. Am J Cardiol. 1991; 68: 80-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Activation of neurohumoral systems following acute myocardial infarction</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>80</fpage>
          <lpage>6</lpage>
          <volume>68</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rouleau</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Moy&#233;</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Champlain</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bichet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Nian M, Lee P, Khaper N, Liu P. Inflamatory    cytokines and post-myocardial infarction remodeling. Circ Res. 2004; 94: 1543-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflamatory cytokines and post-myocardial infarction remodeling</article-title>
          <source>Circ Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1543</fpage>
          <lpage>53</lpage>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Khaper</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive    left ventricular dysfunction and remodeling after myocardial infarction: potential    mechanisms and early predictors. Circulation. 1993; 87: 755-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors</article-title>
          <source>Circulation</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>755</fpage>
          <lpage>63</lpage>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gaudron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Eilles</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kugler</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ertl</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Anand IS, Florea VG, Solomon SD, Konstam    MA, Udelson JE. Noninvasive assessment of left ventricular remodeling: concepts,    techniques and implications for clinical trials. J Card Fail. 2002; 8 (Suppl    6): S452-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive assessment of left ventricular remodeling: concepts, techniques and implications for clinical trials</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>S452</fpage>
          <lpage>64</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Florea</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Udelson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Rajabi M, Kassiotis C, Razeghi P, Taegtmer    H. Return to the fetal gene program protects the stressed heart: a strong hypothesis.    Heart Fail Rev. 2007; 12: 331-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Return to the fetal gene program protects the stressed heart: a strong hypothesis</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>331</fpage>
          <lpage>43</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rajabi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kassiotis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Razeghi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Taegtmer</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Hutchins GM, Bulkley BH. Infarction expansion    versus extension: two different complications of acute myocardial infarction.    Am J Cardiol. 1978: 73: 843-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Infarction expansion versus extension: two different complications of acute myocardial infarction</article-title>
          <source>Am J Cardiol.</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>843</fpage>
          <lpage>9</lpage>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hutchins</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Bulkley</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Zornoff LAM, Matsubara BB, Matsubara LS,    Minicucci MF, Azevedo PS, Campana AO, et al. Cigarette smoke exposure intensifies    ventricular remodeling process following myocardial infarction. Arq Bras Cardiol.    2006; 86: 276-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cigarette smoke exposure intensifies ventricular remodeling process following myocardial infarction</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>276</fpage>
          <lpage>82</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Minicucci</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Campana</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Nicolau JC, Maia LN, Vitola J, Mahaffey KW,    Machado MN, Ramires JF. Baseline glucose and left ventricular remodeling after    acute myocardial infarction. J Diabetes Complications. 2007; 21: 294-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Baseline glucose and left ventricular remodeling after acute myocardial infarction</article-title>
          <source>J Diabetes Complications</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>294</fpage>
          <lpage>9</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nicolau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Maia</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Vitola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mahaffey</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Nicolau JC, Maia LN, Vitola J, Vaz VD, Machado    MN, Godoy MF, et al. ST-segment resolution and late (6-month) left ventricular    remodeling after acute myocardial infarction. Am J Cardiol. 2003; 91: 451-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ST-segment resolution and late (6-month) left ventricular remodeling after acute myocardial infarction</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>451</fpage>
          <lpage>3</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nicolau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Maia</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Vitola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vaz</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Godoy</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Caldas MA, Kowatsch I, Andrade JL, Nicolau    JC, Ramires JF, Mathias W Jr. Value of myocardial contrast echocardiography    for predicting left ventricular remodeling and segmental functional recovery    after anterior wall acute myocardial infarction. J Am Soc Echocardiogr. 2004;    17: 923-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Value of myocardial contrast echocardiography for predicting left ventricular remodeling and segmental functional recovery after anterior wall acute myocardial infarction</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>923</fpage>
          <lpage>32</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Caldas</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kowatsch</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Nicolau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Mathias Jr</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Tiyyagura SR, Pinney S. Left ventricular    remodeling after myocardial infarction: past, present, and future. Mt Sinai    J Med. 2006; 73: 840-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular remodeling after myocardial infarction: past, present, and future</article-title>
          <source>Mt Sinai J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>840</fpage>
          <lpage>51</lpage>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tiyyagura</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Pinney</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Opie LH, Commenford PJ, Gersh BJ, Pfeffer    MA. Controversies in ventricular remodeling. Lancet. 2006; 367: 356-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Controversies in ventricular remodeling</article-title>
          <source>Lancet</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>356</fpage>
          <lpage>67</lpage>
          <volume>367</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Opie</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Commenford</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. McMullen JR, Jennings GL. Differences between    pathological and physiological cardiac hypertrophy: novel therapeutic strategies    to treat heart failure. Clin Exp Pharmacol Physiol. 2007; 34: 255-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure</article-title>
          <source>Clin Exp Pharmacol Physiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>255</fpage>
          <lpage>62</lpage>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McMullen</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Jennings</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Dorn II GW. The fuzzy logic of physiological    cardiac hypertrophy. Hypertension. 2007; 49: 962-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The fuzzy logic of physiological cardiac hypertrophy</article-title>
          <source>Hypertension</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>962</fpage>
          <lpage>70</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dorn II</surname>
              <given-names>GW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Selvetella G, Hirsh E, Notte A, Tarone G,    Lembo G. Adaptive and maladaptive hypertrophy pathways: points of convergence    and divergence. Cardiovasc Res. 2004; 63: 373-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adaptive and maladaptive hypertrophy pathways: points of convergence and divergence</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>373</fpage>
          <lpage>80</lpage>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Selvetella</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Notte</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tarone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lembo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Drakos SG, Terrovitis JV, Anastasious-Nana    MI, Nanas JN. Reverse remodeling during long-term mechanical unload of the left    ventricle. J Moll Cell Cardiol. 2007; 43: 231-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reverse remodeling during long-term mechanical unload of the left ventricle</article-title>
          <source>J Moll Cell Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>231</fpage>
          <lpage>42</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Drakos</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Terrovitis</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Anastasious-Nana</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Nanas</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Zornoff LAM, Matsubara BB, Matsubara LS,    Paiva SAR, Spadaro J. Early rather than delayed administration of lisinopril    protects the heart after myocardial infarction in rats. Basic Res Cardiol. 2000;    95: 208-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Early rather than delayed administration of lisinopril protects the heart after myocardial infarction in rats</article-title>
          <source>Basic Res Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>208</fpage>
          <lpage>14</lpage>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. St John Sutton M, Pfeffer MA, Plappert T,    Rouleau JL, Moy&#233; LA, Dagenais GR, et al. Quantitative two-dimensional    echocardiographic measurements are major predictors of adverse cardiovascular    events after myocardial infarction: the protective effects of captopril. Circulation.    1994; 89: 68-75.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after myocardial infarction: the protective effects of captopril</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>68</fpage>
          <lpage>75</lpage>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>St John Sutton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Plappert</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rouleau</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Moy&#233;</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Dagenais</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Pfeffer MA, Lamas GA, Vaughan DE, Parisi    AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after    anterior myocardial infarction. N Engl J Med. 1988; 319: 80-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>80</fpage>
          <lpage>6</lpage>
          <volume>319</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lamas</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Parisi</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Zornoff LAM, Matsubara LS, Matsubara BB,    Paiva SAR, Spadaro J. Effects of losartan on ventricular remodeling in experimental    infarction in rats. Arq Bras Cardiol. 2000; 75: 459-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of losartan on ventricular remodeling in experimental infarction in rats</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>459</fpage>
          <lpage>70</lpage>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau    JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial    infarction complicated by heart failure, left ventricular dysfunction, or both.    N Engl J Med. 2003; 349: 1893-906.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1893</fpage>
          <lpage>906</lpage>
          <volume>349</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Velazquez</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Rouleau</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Kober</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Maggioni</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Dargie HJ. Effect of carvedilol on outcome    after myocardial infarction in patients with left-ventricular dysfunction: the    CAPRICORN randomised trial. Lancet. 2001; 357: 1385-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial</article-title>
          <source>Lancet</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1385</fpage>
          <lpage>90</lpage>
          <volume>357</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dargie</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Pitt B, Remme W, Zannad F, Neaton J, Martinez    F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients    with left ventricular dysfunction after myocardial infarction. N Engl J Med.    2003; 348: 1309-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1309</fpage>
          <lpage>21</lpage>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pitt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Remme</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zannad</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Neaton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Roniker</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B56">
        <mixed-citation>56. Carluccio E, Biagioli P, Alunni G, Murrone    A, Giambolini G, Ragni T, et al. Patients with hibernating myocardium show altered    left ventricular volumes and shape, which revert after revascularization: evidence    that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol.    2006; 47: 969-77.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>969</fpage>
          <lpage>77</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carluccio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Biagioli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alunni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Murrone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giambolini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ragni</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B57">
        <mixed-citation>57. Rahimtoola SH. Hibernating myocardium: another    piece of the puzzle falls into place. J Am Coll Cardiol. 2006; 47: 978-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hibernating myocardium: another piece of the puzzle falls into place</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>978</fpage>
          <lpage>80</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Ventricular remodeling after myocardial infarction: concepts and clinical implications</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p><undefined id="tx-body2"/>Ventricular remodeling after myocardial infarction: concepts and clinical implications</p>
      <p>
        <bold>Leonardo A M Zornoff; Sergio A R Paiva; Daniella R Duarte; Joel Spadaro</bold>
      </p>
      <p>Faculdade de Medicina de Botucatu, SP -Brazil</p>
      <p>Mailing address</p>
      <p><bold>Key words:</bold> Ventricular remodeling; myocardial infarction; myocardial ischemia; ventricular dysfunction.</p>
      <p>Remodeling process after acute myocardial infarction (AMI) is clinically characterized by ventricular cavity increase. In the acute phase, ventricular dilation is a result of infarction expansion process, whereas late cavity dilation is the result of the eccentric hypertrophy process. </p>
      <p>Ventricular remodeling plays a key role in the pathology of post-infarction ventricular dysfunction. When reacting to aggression, the genetic, structural, and biochemical changes arising from that process will result in the deterioration of the functional ability of the heart in the long run. Signs and symptoms of the onset of heart failure and/or sudden death will result. The mechanisms that have been proposed for the onset of ventricular dysfunction are complex, but the ones to be pointed out are changes in: calcium transit; beta-adrenergic pathway; contractile proteins; increased cell death; collagen accumulation; methaloproteases; higher oxidative stress; energy deficit; cytoskeletal, membrane and matrix proteins; and ventricular geometry. Additionally, remodeling is associated to higher prevalence of cardiac rupture, arrhythmia, and aneurysm formation after infarction.</p>
      <p>Remodeling is therefore associated to impaired post-infarction prognosis. As a result, a better understanding of such process is critical since remodeling course can be modified through a number of therapeutic interventions. </p>
      <p>
        <bold>Background</bold>
      </p>
      <p>The word 'remodeling' was used for the first time in association with myocardial ischemia in 1982 by Hockman and Buckey while addressing the replacement of necrotic tissue infarcted with healing tissue<sup>1</sup>. In 1985, Janice Pfeffer was the first researcher to use the word 'remodeling' in its current meaning. Remodeling was used to characterize the increase of left ventricular cavity in an experimental model in rats<sup>2</sup>. In the following years, the word was occasionally used in articles on morphological changes following acute myocardial infarction (AMI). In 1990, Pfeffer and Braunwald<sup>3</sup> published a review on post-AMI remodeling. The expression was created to characterize the post-infarction morphological changes, specifically ventricular cavity increase. In that article the authors emphasized that the remodeling process resulted in ventricular dysfunction<sup>3</sup>. In the years that followed, the word 'remodeling' was widely used to encompass a large variety of clinical scenarios. In the year 2000 an international forum defined remodeling as molecular, cellular, and interstitial cardiac variations that have clinical manifestations through changes in heart size, mass, geometry and function as a response to a given aggression. (<xref ref-type="fig" rid="fig01-body2">Figure 1</xref>)<sup>4,5</sup>. </p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf01-en.jpg"/></fig>
      <p>
        <bold>Remodeling characterization after AMI </bold>
      </p>
      <p>Interfibrillar collagen disintegrates concurrently to myofibrils necrosis. The region is more bound to distension due to the loss of that support tissue; and consequently, more susceptible to deformations. Therefore, necrotic areas may slide and realign myocites on the infarcted wall. As a result, affected area thinning and cavity dilation are observed. That acute ventricular dilation &#150; characterized by infarcted wall thinning an distension &#150; is defined as infarction expansion<sup>1,6</sup>.</p>
      <p>Chronically, it must be taken into account that in normal hearts both systolic and diastolic tension are at maximal value at midventricle, intermediate level at the base, and lowest level at the apex. As a result of post-infarction expansion, the ventricle loses its elliptical form and takes up spherical configuration. Under this new format, apical parietal tension is significantly increased to reach midventricle level, with midventricle level also being increased. In addition to that redistribution, diastolic parietal tension is shown to be significantly higher than systolic tension. Stress increase is believed to stimulate sarcomeres replication, preferably in a serial fashion. As a result of the interaction of those factors, the ratio cavity radium/wall thickness is typically increased, thus characterizing the eccentric ventricular hypertrophy<sup>3,4,7</sup>. Therefore, chronic ventricular dilation secondary to eccentric hypertrophy is the adaptation to allow for ventricular function maintenance, opposedly to parietal stress increase (<xref ref-type="fig" rid="fig02-body2">Figure 2</xref>).</p>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf02-en.jpg"/></fig>
      <p>Therefore, following acute myocardial infarction the remodeling process is clinically characterized by ventricular cavity increase. In the acute phase, ventricular dilation is the result of the infarction expansion process, whereas late cavity dilation is the result of the eccentric hypertrophy process.</p>
      <p>
        <bold>Consequences from remodeling</bold>
      </p>
      <p>As a result of infarcted wall thinning and growth in AMI acute phase, the concept that prevails is that expansion predisposes the onset of ventricular rupture, also contributing with the anatomic substratum for future aneurysm formation<sup>3</sup>.</p>
      <p>In regard to the functional aspects, we should consider that ejection volume reduction is expected as a result of post-AMI muscular tissue loss, with LV final systolic and diastolic volume increased. The process results in diastolic pressure (pre-load) increase and ventricular dilation. Contractility tends to be restored through Frank-Starling mechanism action, thus restoring, at an early stage, ventricular filling pressures.</p>
      <p>Chronically, however, ventricular remodeling plays a key role in the pathophysiology of ventricular dysfunction. When reacting to injury, the genetic, structural, and biochemical changes arising from that process will result in the deterioration of the functional ability of the heart in the long run. Signs and symptoms of the onset of heart failure and/or sudden death will result<sup>3-5,7</sup>. </p>
      <p>Although the concept that ventricular remodeling results in ventricular function progressive deterioration still prevails, the mechanisms that trigger such phenomenon have not been fully understood to this point in time. Irrespective of any stimulus, one of the most outstanding characteristics in remodeling is the change in the expression pattern of a number of proteins, with an increase or the re-expression of fetal period genes. The causes and possible benefits or drawbacks for such behavior have not been fully understood. It is well accepted, however, that fetal genetic expression is both a marker and can also be related to the very mechanisms involved in remodeling process progress, up to the onset of ventricular dysfunction<sup>5,8</sup>. </p>
      <p>Some of the potential factors involved in the progressive deterioration of ventricular function in the remodeled heart will be discussed further on.</p>
      <p>
        <bold>Calcium transit </bold>
      </p>
      <p>Calcium transit through the sarcoplasmatic reticle is an active, complex process that involves a number of components. Calcium membrane systems as well as calcium intracellular systems (L-type channels, rianodin, calsequestrin) regulate the amount of calcium offer to contractile proteins in the contraction process. Likewise, calmodulin kinase activation and phospholambam phosphorilase stimulate the enzymes (SR-Ca<sup>++</sup>-ATPase or SERCA-2) that are responsible for the highest calcium uptake through the sarcoplasmatic reticle, thus promoting improved relaxation<sup>9</sup>.</p>
      <p>Evidence is available on a number of changes in calcium transit under ventricular remodeling and dysfunction, as for instance changes in the L-channels, rianodin receptors, reduced calsequestrin and calmodulin kinase activity, phospholambam phosphorilase reduction and SERCA-2 activity reduction<sup>9</sup>.</p>
      <p>
        <bold>Changes in the beta-adrenergic pathway </bold>
      </p>
      <p>The interaction of catecholamines and their receptor, followed by the conversion of extracellular stimulus into intracellular response, is defined as the beta-adrenergic pathway<sup>10</sup>. Mediated by regulating protein (protein G), the extracellular stimulus acts on &#946;1 and &#946;2 receptors which, in their turn, interact with the effector by activating or inhibiting the production of 3'5'cyclic adenosine monophosphate (cAMP) and kinases. Adenyl cyclase activity is modulated by two G proteins: the Gs, with the ability to stimulate adenyl cyclase activation and Gi, that can inhibit such activation. The activation of G proteins and cAMP/kinase complex promotes cytosolic calcium increase, thus resulting in a positive inotropic effect. </p>
      <p> A number of changes have been identified in the beta-adrenergic pathway under the pathologic conditions remodeling occurs: &#946;1 receptors concentration reduction, &#946;2 receptors concentration increase, lower levels of Gs protein, higher levels of Gi protein, and adenyl cyclase activity reduction. Therefore, as it occurs with calcium transit, beta-adrenergic pathway will most likely play a key role in cardiac function deterioration in the remodeled heart<sup>10</sup>.</p>
      <p>
        <bold>Changes in contractile proteins </bold>
      </p>
      <p> Ventricular remodeling is characterized by changes in the most important contractile protein &#150; myosin. Myosin contains one pair of heavy chains (&#945; and &#946;) and two pairs of light chains. Depending on chain composition, three isoenzymes may be identified (V1, V2 and V3) in the myocardium of different species. Those isoenzymes contain the same pairs of light chains, the only difference being in regard to heavy chains composition (&#945;&#945; in V1, &#945;&#946; in V2 and &#946;&#946; in V3). Myosin ATPase capacity depends on native sites in the heavy chains, with &#945; fraction showing the highest ATPse capacity. Therefore, isoenzyme composition determines myocyte contractile capacity. In addition to the predominance of myosin light chains fetal form during remodeling, V3 isoform is typically increased, associated to V1 isoform reduction<sup>8</sup>. </p>
      <p>
        <bold>Cell death </bold>
      </p>
      <p>Three myocyte death mechanisms may be identified: apoptosis, or programmed cell death; autophagic; and necrosis. The role played by those three cell death mechanisms in cardiac function deterioration has been studied in a number of models<sup>11</sup>. However, their contribution for or involvement in ventricular dysfunction and remodeling is still controversial. In spite of that, myocyte progressive loss is accepted as present in the different ventricular remodeling models and may play a role in function deterioration following AMI<sup>12</sup>. </p>
      <p>
        <bold>Fibrosis</bold>
      </p>
      <p>Myocytes make up only 30% of the total number of myocardial cells. Complex, organized collagen connections surround and interconnect all those structures. Interstitial collagen fibers are predominantly of types I and III (95% of total collagen). Interconnections major functions are: apoptosis regulation; pathologic deformation resistance; structural alignment maintenance; cardiac distension regulation; and force transmission during cardiac fiber shortening. Collagen tissue is, therefore, a key modulator both for diastolic and systolic cardiac function<sup>13</sup>. </p>
      <p>A solid body of evidence is available to show post-AMI collagen accumulation (fibrosis) in infarction remote areas. Under such condition, fibrosis is associated to ventricular function deterioration<sup>13</sup>. </p>
      <p>
        <bold>Changes in metalloproteinases</bold>
      </p>
      <p>Collagen fibers are typically firmly juxtaposed, with strong chemical binding. They are resistant to the degradation caused by most proteinases. Some enzymes, however, have collagenolytic activity. Among those, the metalloproteinases stand out. Those enzymes are in their inactive form (latent proenzyme), and may be activated by a number of stimuli: mechanic; ischemic; angiotensin II; endothelin 1; catecholamine; tumoral necrosis factor; and interleukin 1 among others<sup>14</sup>.</p>
      <p>Interfibrillar collagen connections breakdown may have quite a number of consequences both in ventricular architecture and function. Increased metalloproteinases activity in rats with acute myocardial infarction, for instance, was associated to progressive ventricular dilation. Likewise, pharmacological inhibition of metalloproteinases in AMI animals attenuated remodeling process, with resulting functional preservation<sup>15,16</sup>. Data available do suggest, therefore, that metalloproteinases play a key role in ventricular remodeling and dysfunction secondary to AMI.</p>
      <p>
        <bold>Increased oxidative stress </bold>
      </p>
      <p>Enough evidence is available to show that AMI results in increased oxidative stress. Reactive Oxygen Species (ROS) come from different sources. Among them, the following stand out: mitochondrial electron transporters; NADPH oxidase system; cyclooxigenase acticity; cytochrome P450; glucose oxidase; xanthine oxidase; lipooxigenase; and catecholamine degradation<sup>17</sup>. Reactive species activate a number of cell signalers which, in the acute phase, contribute for inflammatory process and healing of infarcted region. Chronically, however, oxidative stress would induce remodeling since it results in mitochondrial dysfunction, metalloproteinases activation, fibrosis, hypertrophy and cell death<sup>18-20</sup>.</p>
      <p>
        <bold>Energy deficit</bold>
      </p>
      <p>Another potential factor in cardiac function changes in the remodeled heart is energy deficit. It results from the unbalance between oxygen offer and consumption. Under normal conditions, free fatty acids (FFA) are a major energy substratum for the heart, with a 60% to 90% contribution. FFA metabolites are involved in ATP production in mitochondrial electron transporters through &#946;-oxidation. Energy produced is stored and transported in the form of phosphocreatine. A number of energy metabolism changes have been identified in remodeling. They are expressed through energy production reduction: reduced use of FFA and increased use of glucose as energy substratum, &#946;-oxidation reduction, and mitochondrial functional changes. Those changes are associated to lower levels of phosphocreatine. As mentioned earlier, that is how ATP is stored<sup>21,22</sup>. As a result, all myocardial proteins with ATPase capacity - as those in myosin heavy chain and those responsible for calcium uptake through the sarcoplasmatic reticle - may present functional deficit and deterioration both in systolic and diastolic function<sup>5</sup>.</p>
      <p>
        <bold>Renin-angiotensin-aldosterone system (RAAS) </bold>
      </p>
      <p>Renin-angiotensin system<sup>4,5,23,24 </sup>deserves to be pointed out in the pathophysiology of post-AMI remodeling process. The activation of that system stimulates the intracellular signaling pathway with resulting myocyte increase and fibroblast protein synthesis, leading to cell hypertrophy and fibrosis. Other effects would be increased vessel permeability; growth factor activation; metalloproteinases activation; hemodynamic overload through vasoconstriction and water retention; increased oxidative stress; and direct cytotoxic effect leading to cell death through necrosis or apoptosis. Therefore, the renin-angiotensin system blocking acts as an attractive strategy for the treatment of post-infarction remodeling as discussed further on.</p>
      <p>
        <bold>Other changes</bold>
      </p>
      <p>Membrane, matrix, and cytoskeletal changes may also be associated to the remodeling process. Remodeled hearts have been reported to show changes in tubulin, desmin, titin, integrins, ADAM (A Desintegrin And Metalloproteinase), membrane metalloproteinases, are associated to ventricular dysfunction<sup>25-27</sup>. Therefore, changes in cytoskeletal, membrane and cell matrix proteins may be involved in the pathophysiology of ventricular dysfunction associated to post-AMI remodeling.</p>
      <p>Additionally, hypertrophy is a major mechanism through which myocytes adapt to a given stimulus. In recent years, post-infarction experimental studies have identified that myocardial contractility remained unchanged in infarcted animals. The phenomenon occurred in spite of left ventricular dilation, which was associated to dysfunction signals and heart failure, as pulmonary congestion. The authors concluded that although infarcted and non-infarcted animals' muscle have the same intrinsic capacity to generate force, infarcted rats presented depressed ventricular function. Therefore, based on the geometric changes that took place, remodeling itself could compromise cardiac global function<sup>28,29</sup>.</p>
      <p>Ventricular remodeling has, then, shown to involve a number of morphological changes in response to a given stimulus or injury. At a first moment, the process may be adaptive, but in the long run, one of the consequences of remodeling would be the onset of progressive ventricular dysfunction. The mechanisms responsible for functional deterioration are not yet fully understood, but they may include genetic, structural, biochemical, and energy changes.</p>
      <p>
        <bold>Ventricular Remodeling Determining Factors </bold>
      </p>
      <p>Post-AMI ventricular remodeling process is not homogeneous. Four factors interfere in the prevalence and intensity of that process:</p>
      <p><bold>1)</bold> Infarction morphologic characteristics. </p>
      <p>Although remodeling may be present at ischemic injuries of different sizes, its predominance has been observed in large size infarctions. Likewise, it seems a minimum injury size (16-20%) is a pre-requisite for remodeling to occur. Another factor is relative to the fact that due to large ventricular curvature and to anteroapical thinning, remodeling frequency occurs in that area, typically in transmural infarctions<sup>3,30,31</sup>. </p>
      <p><bold>2)</bold> Healing Characteristics. </p>
      <p>In the early post-AMI period significant collagen volume increase is observed in the infarcted area. At a first moment, Type III collagen is increased. Type III is known to have lower resistance to deformation of Type I collagen &#150; harder, and predominant in normal hearts. With time, Type III collagen is reduced, and Type I grows higher. Newly formed collagen is admittedly less hard than mature collagen. Associated to the predominance of Type III collagen, that will determine the potential vulnerability of healed area to possible deforming forces. Therefore, AMI cicatrization is an intervention-sensitive dynamic process<sup>32</sup>. For illustration purposes: the administration of NSAIDS or corticosteroid resulted in slower healing, which turned the area more susceptible to deformations after marked ventricular expansion3. </p>
      <p><bold>3)</bold> Hemodynamic Stress. </p>
      <p>Load condition fluctuations of the working heart are known to occur relative to hemodynamic stress during infarction. It has been well documented in the literature that cardiac overload interferes in the remodeling process<sup>3-5</sup>. Experimental studies have shown, for instance, that maneuvers such as aortic constriction, metoxamin infusion and early physical exercise have resulted in larger ventricular dilation when control animals are compared to. Likewise, hypertensive humans have presented a more intense remodeling process<sup>3</sup>.</p>
      <p><bold>4)</bold> Modulators. </p>
      <p>Infarction is most typically characterized by increased levels of a number of modulators, such as: angiotensin II; endothelin 1; catecholamine; tumoral necrosis factor; interleukin 1 and 6; transforming growth factor beta-1; and insulin-like growth factor 1 (IGF-1). It has been admitted that those increased levels play a pathophysiological role, since the different modulators regulate initial infarction events such as inflammatory reaction and healing. In addition, they result in hemodynamic and inotropic effects that act as counterparts to the loss of contractile tissue for the hemodynamic stabilization of patients. Under physiologic situations, the levels of modulators go back to normal within a week's time. In some cases, however, those levels may be kept high. Experimental models have shown that modulators increased levels may both trigger and regulate cardiac remodeling<sup>33,34</sup>. </p>
      <p>
        <bold>Ventricular remodeling natural history</bold>
      </p>
      <p>After infarction, approximately 50% of patients develop some degree of left ventricular dilation. From those, 50% of patients develop progressive ventricular chamber increase, while 50% are kept stable. From those without dilation in the acute phase, a non-defined number will present remodeling after some weeks, months, or years after the ischemic insult<sup>35</sup>.</p>
      <p>
        <bold>Diagnosis</bold>
      </p>
      <p>Post-infarction remodeling clinical diagnosis is based on the identification of left ventricle cavity enlargement. In order to reach diagnosis, the most commonly used methods are echocardiogram, ventriculography, and MRI. It has been admitted that MRI provides better sensitivity for the detection of changes that occurred in left ventricular cavity. However, due to costs and technical requirements, its clinical application is still limited. As a result, in clinical practice and in major clinical trials, the most commonly used method for remodeling diagnosis is echocardiogram<sup>36</sup>. </p>
      <p>Another possibility for diagnosis - for the time being used only in experimental models and isolated clinical reports - is based on the detection of cell markers that characterize fetal genotype. Among those, the following are to be mentioned: changes in myosin heavy chain, with &#945;-myosin reduction and &#946;-myosin increase, &#945;-actin increase; natriuretic peptide increase; GLUT4 reduction and GLUT1 increase; SERCA-2a reduction and angiotensin converting enzyme increase<sup>3-5,8,37</sup>.</p>
      <p>
        <bold>Differential diagnosis</bold>
      </p>
      <p>Muscle bundle sliding &#150; typical in abrupt, intense infarction &#150; may result in precordial pain of variable magnitude. Another aspect to be considered is that although the expansion does not change necrotic tissue volume, fiber sliding increases infarcted myocardial surface. Therefore, ST segment elevation may be intensified in already compromised leads, or else, changes may occur in ST segment leads that were not compromised at a first moment. Additionally, in extreme cases, some blood may be retained in the expanded region during systole, thus resulting in systolic volume reduction and hemodynamic compromising<sup>38</sup>.</p>
      <p>As a result, major differential diagnosis for infarction expansion is infarction extension. (<xref ref-type="table" rid="tab01-body2">Table 1</xref>). While expansion is a frequent event (50%), extension occurs in less than 20% of AMI cases. Expansion is more frequently observed on the first days after infarction in anterior wall transmural large size infarctions. Extension may occur any time. However, a major distinction between the two complications is that extension is associated to new enzyme increase, since it implies new necrotic foci<sup>38</sup>.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Remodeling prediction factors</bold>
      </p>
      <p>As mentioned earlier, a number of factors favor the onset of remodeling, the major ones being: large, transmural, anterior infarctions; ejection fraction decrease; absence of or inefficacy of reperfusion; no-reflow phenomenon; early coronary reocclusion; high blood pressure; and the use of NSAIDS and corticosteroid in AMI acute phase (<xref ref-type="table" rid="tab02-body2">Table 2</xref>)<sup>3,4,35</sup>. More recently, experimental data have suggested that smoking may intensify post-AMI remodeling<sup>39</sup>. Likewise, a recent clinical trial has suggested that high baseline glycemia may also predict remodeling<sup>40</sup>. On the other hand, small size, subendocardial infarctions, inferior infarctions, presence of maintained reperfusion evaluated by ST segment resolution, permeable microcirculation, previous angina, lack of comorbidities and certain drugs prevent the onset of remodeling<sup>3,4,35,41-43</sup>.</p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>Controversies about post-AMI remodeling </bold>
      </p>
      <p>Although remodeling is one of the most comprehensively studied topics in recent years, a number of issues are still controversial. </p>
      <p>Firstly, infarction is characterized by cardiac tissue death, which is replaced by healing tissue. Therefore, conceptually, every infarcted heart changes its composition, which means to say, suffers remodeling. Clinically, however, as already discussed, the word 'remodeling' is commonly used after infarction to mean ventricular cavity pathologic enlargement. </p>
      <p>Another aspect to be considered is that the word 'remodeling' is commonly used to characterize pathologic adaptations. But such concept not always applies. As discussed earlier, 50% of patients develop ventricular cavity enlargement in the post-infarction acute phase. Only 50% of those patients, however, presents progressive cavity enlargement and impaired ventricular function. The other patients are kept stable, both morphologically and functionally, which suggests that in those patients cavity enlargement may be adaptive, with no deleterious consequences. Additionally, a number of transgenic animal models present ventricular dilation and hypertrophy in response to different overloads, but no signs of ventricular dysfunction or survival compromising<sup>44</sup>. Evidence accumulated to this point in time, therefore, suggest that under certain situations remodeling may be adaptive and contribute for ventricular function maintenance in response to certain stimuli (adaptive or physiologic remodeling). In addition, it has been admitted that this adaptive process would be modulated by different cell signaling pathways (phosphatidylinositol-3 kinase) of the pathways involved in pathologic remodeling (phospholipase C, protein kinase C and calcineurin)<sup>45-47</sup>.</p>
      <p>Finally, it is important to point out that remodeling is a very complex process, and implies genetic, cellular and molecular changes. Morphological changes as post-infarction cavity enlargement, for instance, are only one way clinicians use to reach diagnosis and stratify the phenomenon. Until recently, strategies aiming at remodeling reversion focused morphological changes regression exclusively. As a result, up to this point in time doubts are still pending whether the regression of morphological changes is associated to the reversion of genetic, biochemimal, and cellular reversion. However, more recent data have suggested that heart failure patients submitted to a few intervention procedures showed that wall thickness and left ventricle cavity volume reduction were associated to: myocite size reduction; calcium transit restorarion; cytoeskeletal and beta-adrenergic pathway improvement; collagen volume reduction; and possible changes in the intracellular pathways that are responsible for remodeling<sup>48</sup>. Remodeling clinical reversion, therefore, seems to be a real event, and is associated to the reversal of process-modulating pathophysiologic changes.</p>
      <p>
        <bold>Remodeling prevention - attenuation - reversion</bold>
      </p>
      <p>Due to its ability to highly reduce infarction size in regard to transmurality, myocardial reperfusion is the best prevention action against remodeling. ASA is the best choice anti-inflammatory in AMI acute phase since it does not interfere in healing characteristics. Another measure is left ventricle parietal stress; therefore, blood pressure increase should be avoided in AMI acute phase.</p>
      <p>As for specific medications, experimental studies have shown that early use of angiotensin converting enzyme (ACEI) inhibitors attenuated remodeling.<sup>(2,49)</sup> That was confirmed through clinical trials.<sup>(50,51)</sup> Likewise, the early administration of angiotensin II AT1 receptor antagonists in rats atennuated remodeling and reduced post-AMI mortality rate.<sup>(52)</sup> Later, clinical trials did not find any difference in ARAII action as compared to ACEI after infarction.<sup>(53)</sup> Although the use of beta-blockers and aldosterone antagonists by ventricular dysfunction patients with &lt;40% ejection fraction is also associated to better prognosis,<sup>(54,55)</sup> the effect of those drugs on patients with no ventricular dysfunction after infarction is not yet known. Finally, it should be considered that revascularization in patients with a hibernating myocardium may be associated to lower remodeling.<sup>(56,57) </sup>Other preventive therapeutic approaches for remodeling prevention, attenuation or reversion after infarction &#150; such as cell regeneration; vasopressin antagonists; natriuretic peptides; ventricular synchronization; mechanic devices; nitrates and statins &#150; still need confirmation through clinical trials.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Ventricular remodeling is a relatively common post-AMI event. The relevance of remodeling is associated to the fact that in addition to resulting in higher cardiac rupture prevalence, arrhythmia and aneurysm formation, the process may modulate the onset and the progression of ventricular dysfunction, heart failure and the outcome of death following infarction. Also to be considered is the fact that this process is not homogenous in AMI patients. Therefore, patients with diagnosed remodeling or under high risk of developing remodeling must be treated in an aggressive fashion in order to prevent, attenuate, or even revert the process. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Remodelaci&#243;n ventricular postinfarto de miocardio: conceptos e implicaciones cl&#237;nicas</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Remodelaci&#243;n ventricular postinfarto de miocardio: conceptos e implicaciones cl&#237;nicas</bold>
          </label>
          <p>
            <bold>Leonardo A. M. Zornoff; Sergio A. R. Paiva; Daniella R. Duarte; Joel Spadaro</bold>
          </p>
        </fn>
      </p>
      <p> Faculdade de Medicina de Botucatu, SP -Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras clave:</bold> Remodelaci&#243;n ventricular, infarto de miocardio, isquemia mioc&#225;rdica, disfunci&#243;n ventricular.</p>
      <p>Tras infarto agudo de miocardio, el proceso de remodelaci&#243;n se caracteriza, cl&#237;nicamente, por aumento de la cavidad ventricular. En la fase aguda, la dilataci&#243;n ventricular es consecuencia del proceso de expansi&#243;n del infarto, mientras que la dilataci&#243;n cavitaria tard&#237;a es consecuencia del proceso de hipertrofia exc&#233;ntrica.</p>
      <p>La remodelaci&#243;n ventricular desempe&#241;a un rol fundamental en la fisiopatolog&#237;a de la disfunci&#243;n del ventr&#237;culo, tras infarto. Al reaccionar a la determinada agresi&#243;n, las alteraciones gen&#233;ticas, estructurales y bioqu&#237;micas de ese proceso resultar&#225;n en deterioraci&#243;n de la capacidad funcional del coraz&#243;n, a largo plazo, y consecuente aparecimiento de las se&#241;ales y s&#237;ntomas de insuficiencia cardiaca y/o muerte s&#250;bita. Los mecanismos propuestos para explicar el aparecimiento de la disfunci&#243;n ventricular son complejos, pero se destacan los que siguen a continuaci&#243;n: cambios en el tr&#225;nsito de calcio; alteraciones de la v&#237;a beta-adren&#233;rgica; alteraciones de las prote&#237;nas contr&#225;ctiles; aumento de la muerte celular; acumulaci&#243;n de col&#225;geno; alteraciones de las metaloproteasas; aumento del estr&#233;s oxidativo; d&#233;ficit energ&#233;tico; alteraciones de las prote&#237;nas del citoesqueleto, de la membrana y de la matriz; y alteraciones de la geometr&#237;a ventricular. Adicionalmente, la remodelaci&#243;n est&#225; asociada a mayor prevalencia de ruptura cardiaca, arritmias y formaci&#243;n de aneurismas, tras infarto.</p>
      <p>La remodelaci&#243;n, por lo tanto, est&#225; asociada a peor pron&#243;stico postinfarto. De ese modo, el entendimiento de ese proceso es cr&#237;tico, pues la evoluci&#243;n de la remodelaci&#243;n se puede cambiar por medio de diversas intervenciones terap&#233;uticas. </p>
      <p>
        <bold>Hist&#243;rico</bold>
      </p>
      <p>El t&#233;rmino remodelaci&#243;n, remodelamiento o remodelaje, se utiliz&#243; por primera vez con relaci&#243;n a isquemia mioc&#225;rdica, en 1982, por Hockman y Buckey, en discusi&#243;n sobre la reemplazo del tejido necr&#243;tico infartado por tejido cicatricial<sup>1</sup>. En 1985, Janice Pfeffer fue la primera investigadora a utilizar el t&#233;rmino remodelaci&#243;n en el contexto actual. En el modelo de infarto experimental en ratas, se utiliz&#243; la remodelaci&#243;n para caracterizar el aumento del tama&#241;o de la cavidad ventricular izquierda<sup>2</sup>. En los a&#241;os siguientes, se utiliz&#243; dicha palabra, de modo espor&#225;dico, en art&#237;culos sobre alteraciones morfol&#243;gicas tras infarto agudo de miocardio (IAM). En 1990, Pfeffer y Braunwald<sup>3</sup> publicaron revisi&#243;n sobre la remodelaci&#243;n tras IAM, y se acu&#241;&#243; la expresi&#243;n para caracterizarse alteraciones morfol&#243;gicas tras infarto, caracter&#237;sticamente el aumento del tama&#241;o de la cavidad ventricular. En ese art&#237;culo, los autores enfatizaban que el proceso de remodelaci&#243;n resultaba en disfunci&#243;n ventricular<sup>3</sup>. En los a&#241;os siguientes, el t&#233;rmino remodelaci&#243;n se aplic&#243; ampliamente, abarcando una gran variedad de situaciones cl&#237;nicas. En 2000, tuvo lugar un foro internacional que ha definido la remodelaci&#243;n como variaciones moleculares, celulares y intersticiales cardiacas, que se manifestar&#237;an cl&#237;nicamente por alteraciones en el tama&#241;o, masa, geometr&#237;a y funci&#243;n del coraz&#243;n, en respuesta a determinada agresi&#243;n (<xref ref-type="fig" rid="fig01-body3">Fig. 1</xref>)<sup>4,5</sup>.</p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf01-es.jpg"/></fig>
      <p>
        <bold>Caracterizaci&#243;n de la remodelaci&#243;n post-IAM</bold>
      </p>
      <p>Simult&#225;neamente a la necrosis de las miofibrillas, hay la desintegraci&#243;n del col&#225;geno interfibrilar. La p&#233;rdida de ese tejido de sustentaci&#243;n convierte la regi&#243;n en m&#225;s propensa a distensi&#243;n y, consecuentemente, m&#225;s susceptible a deformaciones. De esa manera, puede ocurrir el deslizamiento muscular en &#225;reas necr&#243;ticas, con realineamiento de los miocitos en la pared infartada. Como consecuencia, resulta el afilamiento de la regi&#243;n alcanzada y la dilataci&#243;n de la cavidad. Esa dilataci&#243;n ventricular aguda, caracterizada por adelgazamiento y distensi&#243;n de la pared infartada, se denomina expansi&#243;n del infarto<sup>1,6</sup>. </p>
      <p>Cr&#243;nicamente, se debe tomar en consideraci&#243;n que, en corazones normales, tanto la tensi&#243;n sist&#243;lica como la diast&#243;lica son m&#225;ximas en la regi&#243;n medial del ventr&#237;culo, de valor intermediario en la base y m&#237;nima en el &#225;pice. Ya en corazones infartados, consecuentemente a la expansi&#243;n, el ventr&#237;culo pierde su forma el&#237;ptica normal, asumiendo una configuraci&#243;n esf&#233;rica. En ese nuevo formato, hay un aumento importante de la tensi&#243;n parietal en el &#225;pice, de modo que dicha tensi&#243;n se iguala a los valores de la regi&#243;n medial, aunque aqu&#237; tambi&#233;n ocurra un aumento de sus valores. Adem&#225;s de esa redistribuci&#243;n de fuerzas, se verifica un aumento significativamente mayor de la tensi&#243;n parietal en la di&#225;stole que en comparaci&#243;n a la s&#237;stole. Se cree que el aumento de ese estr&#233;s estimular&#237;a la replicaci&#243;n de los sarc&#243;meros, de preferencia en serie. Com&#250;nmente, en raz&#243;n de la interacci&#243;n de esos factores, la relaci&#243;n rayo de la cavidad/espesor de la pared aumenta, caracteriz&#225;ndose la hipertrofia ventricular del tipo exc&#233;ntrica<sup>3,4,7</sup>. As&#237;, esa dilataci&#243;n ventricular cr&#243;nica, secundaria a la hipertrofia exc&#233;ntrica, ser&#237;a una adaptaci&#243;n que permitiera el mantenimiento de la funci&#243;n ventricular, en contraposici&#243;n al aumento del estr&#233;s parietal (<xref ref-type="fig" rid="fig02-body3">Fig. 2</xref>).</p>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gf02-es.jpg"/></fig>
      <p>De esa manera, tras infarto agudo de miocardio, el proceso de remodelaci&#243;n se caracteriza, cl&#237;nicamente, por aumento de la cavidad ventricular. En la fase aguda, la dilataci&#243;n ventricular es consecuencia del proceso de expansi&#243;n del infarto, mientras que la dilataci&#243;n cavitaria tard&#237;a es consecuencia del proceso de hipertrofia exc&#233;ntrica. </p>
      <p>
        <bold>Consecuencias de la remodelaci&#243;n</bold>
      </p>
      <p>En la fase aguda del IAM, en consecuencia del afilamiento y crecimiento de la pared infartada, prevalece el concepto de que la referida expansi&#243;n predispone al aparecimiento de ruptura ventricular, as&#237; como representa el sustrato anat&#243;mico para la posterior formaci&#243;n de aneurismas<sup>3</sup>.</p>
      <p>Con relaci&#243;n a los aspectos funcionales, debemos tomar en consideraci&#243;n que tras IAM, en consecuencia de la p&#233;rdida de tejido muscular, es com&#250;n el descenso del volumen eyectado, con aumento del volumen sist&#243;lico final y diast&#243;lico final del VI. Ese proceso resulta en aumento de la tensi&#243;n diast&#243;lica (precarga) y dilataci&#243;n ventricular. Por la acci&#243;n del mecanismo de Frank-Starling, la contractilidad tiende a restaurarse, restableciendo, en una fase inicial, las presiones de llenado ventricular.</p>
      <p>Cr&#243;nicamente, sin embargo, el proceso de remodelaci&#243;n ventricular desempe&#241;a un rol fundamental en la fisiopatolog&#237;a de la disfunci&#243;n ventricular. Al reaccionar a la determinada injuria, las alteraciones gen&#233;ticas, estructurales y bioqu&#237;micas de ese proceso resultar&#225;n en deterioraci&#243;n de la capacidad funcional del coraz&#243;n, a largo plazo, y consecuente aparecimiento de las se&#241;ales de insuficiencia cardiaca y/o muerte s&#250;bita<sup>3-5,7</sup>. </p>
      <p>Pese a la prevalencia del concepto de que la remodelaci&#243;n ventricular resulta en deterioraci&#243;n progresiva de la funci&#243;n ventricular, los mecanismos responsables por ese fen&#243;meno no est&#225;n todav&#237;a completamente aclarados. Independientemente del est&#237;mulo, una de las caracter&#237;sticas m&#225;s destacadas de la remodelaci&#243;n es la modificaci&#243;n del est&#225;ndar de expresi&#243;n de diversas prote&#237;nas, con el aumento o la reexpresi&#243;n de genes del per&#237;odo fetal. Las causas y las posibles ventajas o desventajas de ese comportamiento no est&#225;n todav&#237;a suficientemente aclaradas. Se acepta, no obstante, que la expresi&#243;n gen&#233;tica fetal sea tanto un marcador como pueda estar relacionada a los mecanismos propiamente implicados en la progresi&#243;n del proceso de remodelaci&#243;n, hasta el aparecimiento de la disfunci&#243;n ventricular<sup>5,8</sup>. </p>
      <p>Se discutir&#225;n a continuaci&#243;n algunos de los potenciales factores implicados en la deterioraci&#243;n progresiva de la funci&#243;n ventricular, en el coraz&#243;n remodelado. </p>
      <p>
        <bold>Tr&#225;nsito de calcio</bold>
      </p>
      <p>El tr&#225;nsito de calcio por el ret&#237;culo sarcoplasm&#225;tico es un proceso activo, complejo, que implica la participaci&#243;n de varios componentes. Por ejemplo, sistemas de membrana e intracelulares de calcio (canales tipo-L, rianodina, calsequestrina) regulan la cantidad de calcio ofertado a las prote&#237;nas contr&#225;ctiles durante el proceso de contracci&#243;n. Del mismo modo, la activaci&#243;n de la calmodulina quinasa y la fosforilaci&#243;n de la fosfolamban estimulan enzimas (SR-Ca<sup>++</sup>-ATPase &#243; SERCA-2) responsables de la mayor captaci&#243;n de calcio por el ret&#237;culo sarcoplasm&#225;tico, promoviendo mejora de la relajaci&#243;n<sup>9</sup>. </p>
      <p>En situaciones de remodelaci&#243;n y disfunci&#243;n ventricular, existen evidencias de diversas alteraciones en el transito de calcio, como modificaciones de los canales-L, receptores da rianodina, disminuci&#243;n de la actividad de la calsequestrina y calmodulina quinasa, reducci&#243;n en la fosforilaci&#243;n de la fosfolamban y reducci&#243;n en la actividad de la SERCA-2<sup>9</sup>.</p>
      <p>
        <bold>Alteraciones de la v&#237;a beta-adren&#233;rgica</bold>
      </p>
      <p>Se denomina v&#237;a beta-adren&#233;rgica<sup>10 </sup>la interacci&#243;n de las catecolaminas con su receptor, seguida de la conversi&#243;n del est&#237;mulo extracelular en respuesta intracelular. El est&#237;mulo extracelular opera sobre los receptores &#946;1 y &#946;2 que, mediado por prote&#237;na reguladora (prote&#237;na G) interacciona con el efector, activando o inhibiendo la producci&#243;n de 3'5'adenos&#237;n monofosfato c&#237;clico (AMPc) y de quinasas. La actividad de la adenilciclasa es modulada por dos prote&#237;nas G: las Gs, con capacidad de estimular la activaci&#243;n da adenilciclasa y la Gi, que es capaz de inhibir esa activaci&#243;n. La activaci&#243;n de la prote&#237;na Gs y del complejo AMPc/quinasa promueve aumento del calcio citos&#243;lico, resultando en efecto inotr&#243;pico positivo. </p>
      <p>En condiciones patol&#243;gicas en que ocurre remodelaci&#243;n, se identificaron diversas alteraciones en la v&#237;a beta-adren&#233;rgica: disminuci&#243;n de la concentraci&#243;n de receptores &#946;1, aumento de la concentraci&#243;n de receptores &#946;2, disminuci&#243;n de los niveles de prote&#237;na Gs, aumento de los niveles de prote&#237;na Gi y reducci&#243;n de la actividad de la adenilciclasa. Por lo tanto, como ejemplo de lo que ocurre con el tr&#225;nsito de calcio, la v&#237;a beta-adren&#233;rgica probablemente desempe&#241;a un rol cr&#237;tico en la deterioraci&#243;n de la funci&#243;n cardiaca en el coraz&#243;n remodelado<sup>10</sup>. </p>
      <p>
        <bold>Alteraci&#243;n de las prote&#237;nas contr&#225;ctiles</bold>
      </p>
      <p>El proceso de remodelaci&#243;n ventricular est&#225; caracterizado por alteraciones en la miosina, la principal prote&#237;na contr&#225;ctil, compuesta de una dupla de cadenas pesadas (&#945; y &#946;) y dos de cadenas ligeras. Dependiendo de la composici&#243;n de las cadenas, podemos identificar tres isoenzimas (V1, V2 y V3) en el miocardio de diferentes especies. Esas isoenzimas poseen las mismas duplas de cadenas ligeras, variando solamente con relaci&#243;n a la composici&#243;n de las cadenas pesadas (&#945;&#945; en las V1, &#945;&#946; en las V2 y &#946;&#946; en las V3). La capacidad ATP&#945;sica de la miosina depende de sitios activos localizados en las cadenas pesadas, y la fracci&#243;n &#945; posee mayor capacidad ATP&#225;sica. Por lo tanto, la composici&#243;n de las isoenzimas determina la capacidad contr&#225;ctil del miocito. Durante la remodelaci&#243;n, adem&#225;s de haber predominio de la forma fetal de las cadenas leves de la miosina, usualmente ocurre aumento de la isoforma V3, seguido de disminuci&#243;n de la isoforma V1<sup>8</sup>. </p>
      <p>
        <bold>Muerte celular</bold>
      </p>
      <p>Podemos identificar tres mecanismos de muerte del miocito: apoptosis, o muerte celular programada, autofagia y necrosis. La participaci&#243;n de los tres diferentes mecanismos de muerte celular en la deterioraci&#243;n de la funci&#243;n cardiaca ha sido estudiada en diversos modelos<sup>11</sup>. Sin embargo, la exacta participaci&#243;n o contribuci&#243;n de los diferentes mecanismos de muerte celular, en el proceso de remodelaci&#243;n y disfunci&#243;n ventricular, es todav&#237;a controvertida. A despecho de ese hecho, se acepta que la p&#233;rdida progresiva de miocitos est&#233; presente en varios modelos de remodelaci&#243;n ventricular y puede participar de la deterioraci&#243;n de la funci&#243;n, tras el IAM<sup>12</sup>. </p>
      <p>
        <bold>Fibrosis</bold>
      </p>
      <p>Los miocitos representan s&#243;lo el 30% del n&#250;mero total de c&#233;lulas mioc&#225;rdicas. Hay una compleja y organizada red de col&#225;geno que circunda e interconecta todas esas estructuras. Las fibras de col&#225;geno encontradas en el intersticio son predominantemente de los tipos I e III (el 95% del col&#225;geno total). Las principales funciones de esa red son: regular la apoptosis; resistir a deformaciones patol&#243;gicas; mantener el alineamiento de las estructuras y regular la distensibilidad cardiaca y la transmisi&#243;n de fuerza durante el acortamiento de la fibra cardiaca. El tejido col&#225;geno, por lo tanto, es un importante modulador tanto de la funci&#243;n cardiaca diast&#243;lica como de la funci&#243;n sist&#243;lica<sup>13</sup>. </p>
      <p>Existe amplia documentaci&#243;n de que, tras IAM, hay la acumulaci&#243;n de col&#225;geno (fibrosis) en las &#225;reas remotas al infarto. Bajo esa condici&#243;n, la fibrosis est&#225; asociada a la deterioraci&#243;n de la funci&#243;n ventricular<sup>13</sup>. </p>
      <p>
        <bold>Alteraciones de las metaloproteasas</bold>
      </p>
      <p>Usualmente, las fibras col&#225;genas se yuxtaponen firmemente, con fuertes enlaces qu&#237;micos y son resistentes a la degradaci&#243;n causada por la mayor&#237;a de las proteasas. Algunas enzimas, con todo, tienen actividad colagenol&#237;tica, y entre ellas se destacan las metaloproteasas. Esas enzimas se encuentran en formas inactivas (proenzima latente), pudiendo activarse por una serie de est&#237;mulos: mec&#225;nicos, isqu&#233;micos, angiotensina II, endotelina 1, catecolaminas, factor de necrosis tumoral, interleucina 1, entre otros<sup>14</sup>. </p>
      <p>La quiebra de la red de col&#225;geno interfibrilar puede provocar innumeras consecuencias, tanto en la arquitectura como en la funci&#243;n ventricular. Por ejemplo, en ratas con infarto agudo de miocardio, al aumento de la actividad de las metaloproteasas se sigui&#243; la dilataci&#243;n ventricular progresiva. De igual manera, la inhibici&#243;n farmacol&#243;gica de las metaloproteasas, en animales con IAM, atenu&#243; el proceso de remodelaci&#243;n, con consecuente preservaci&#243;n funcional<sup>15,16</sup>. Los datos disponibles, por lo tanto, sugieren una participaci&#243;n importante de las metaloproteasas en la remodelaci&#243;n y disfunci&#243;n ventricular secundaria al IAM. </p>
      <p>
        <bold>Aumento del estr&#233;s oxidativo</bold>
      </p>
      <p>Ya est&#225; bien documentado que el IAM resulta en aumento de estr&#233;s oxidativo. Son varias las procedencias de las especies reactivas de ox&#237;geno, y entre ellas se destacan: los transportadores de electrones mitocondriales, el sistema NADPH oxidasa, la actividad de la ciclooxigenasa, el citocromo P450, glucosa oxidasa, xantina oxidasa, lipoxigenasa y degradaci&#243;n de las catecolaminas17. Las especies reactivas activar&#237;an diversas se&#241;ales celulares que, en la fase aguda, participar&#237;an del proceso inflamatorio y de la cicatrizaci&#243;n de la regi&#243;n infartada. Cr&#243;nicamente, sin embargo, el estr&#233;s oxidativo inducir&#237;a a la remodelaci&#243;n por resultar en disfunci&#243;n mitocondrial, activaci&#243;n de las metaloproteasas, fibrosis, hipertrofia y muerte celular18-20.</p>
      <p>
        <bold>D&#233;ficit energ&#233;tico</bold>
      </p>
      <p>Otro factor potencialmente responsable por la alteraci&#243;n de la funci&#243;n cardiaca en el coraz&#243;n remodelado es el d&#233;ficit energ&#233;tico, que resulta del desequilibrio entre oferta y consumo de ox&#237;geno. En condiciones normales, los &#225;cidos grasos libres (AGL) son el principal sustrato energ&#233;tico del coraz&#243;n, con participaci&#243;n variando del 60% al 90%. Por medio del proceso de &#946;-oxidaci&#243;n, metabolitos de los AGL participan en la producci&#243;n de ATP en los transportadores de electrones en la mitocondria. Tras la producci&#243;n, se almacena la energ&#237;a producida y se la transporta en la forma de fosfocreatina. Ya se identificaron diversas alteraciones del metabolismo energ&#233;tico en la remodelaci&#243;n, que se manifiestan con disminuci&#243;n de la producci&#243;n de energ&#237;a: disminuci&#243;n en la utilizaci&#243;n de los AGL y aumento de la utilizaci&#243;n de glucosa como sustrato energ&#233;tico, reducci&#243;n de la &#946;-oxidaci&#243;n y alteraciones funcionales mitocondriales. Esas alteraciones est&#225;n asociadas a la disminuci&#243;n de los niveles de fosfocreatina que, como se dijo anteriormente, representa la forma en la que el ATP se almacena<sup>21,22</sup>. Como consecuencia, todas las prote&#237;nas mioc&#225;rdicas con capacidad ATP&#225;sica, tales como las de la cadena pesada de la miosina y las responsables de la captaci&#243;n de calcio por medio del ret&#237;culo sarcoplasm&#225;tico, pueden presentar d&#233;ficit en sus funciones, con deterioraci&#243;n tanto de la funci&#243;n cardiaca sist&#243;lica como de la dist&#243;lica<sup>5</sup>.</p>
      <p>
        <bold>Sistema renina-angiotensina-aldosterona</bold>
      </p>
      <p>En la fisiopatolog&#237;a del proceso de remodelaci&#243;n post-IAM, merece destaque la participaci&#243;n del sistema renina-angiotensina-aldosterona<sup>4,5,23,24</sup>. La activaci&#243;n de ese sistema estimula v&#237;as de se&#241;alizaci&#243;n intracelulares, con consecuente aumento de la s&#237;ntesis proteica en miocitos y fibroblastos, lo que causa hipertrofia celular y fibrosis. Otros efectos ser&#237;an el aumento de la permeabilidad de los vasos, activaci&#243;n de factores de crecimiento, activaci&#243;n de las metaloproteasas, sobrecarga hemodin&#225;mica por vasoconstricci&#243;n y retenci&#243;n h&#237;drica, aumento del estr&#233;s oxidativo y efecto citot&#243;xico directo, conduciendo a la muerte celular por necrosis o apoptosis. De esa manera, el bloqueo del sistema renina-angiotensina es una estrategia atrayente para el tratamiento de la remodelaci&#243;n postinfarto, como se ver&#225; a continuaci&#243;n.</p>
      <p>
        <bold>Otras alteraciones</bold>
      </p>
      <p>Alteraciones de las prote&#237;nas de membrana, de la matriz y del citoesqueleto tambi&#233;n pueden seguir el proceso de remodelaci&#243;n. Existen relatos de que en el coraz&#243;n remodelado, alteraciones de tubulina, desmina, titina, integrinas, ADAM (<italic>A Desintegrin And Metaloproteinase</italic>), metaloproteasas de membrana, trombospondina 2, osteopontina y tenascina C est&#225;n relacionadas a la disfunci&#243;n ventricular<sup>25-27</sup>. Por lo tanto, alteraciones de las prote&#237;nas del citoesqueleto, de la membrana y de la matriz celular podr&#237;an participar en la fisiopatolog&#237;a de la disfunci&#243;n ventricular, que sigue junto a la remodelaci&#243;n tras IAM.</p>
      <p>Adicionalmente, uno de los principales mecanismos por medio de los cuales el miocito se adapta a un determinado est&#237;mulo es el proceso de hipertrofia. En los &#250;ltimos a&#241;os, estudios experimentales, tras infarto, han verificado que la contractilidad mioc&#225;rdica de los animales infartados no presentaba alteraciones. Ese fen&#243;meno ocurr&#237;a a pesar de la presencia de dilataci&#243;n ventricular izquierda, seguida de se&#241;ales de disfunci&#243;n y de insuficiencia cardiaca, como congesti&#243;n pulmonar. Los autores concluyeron que, a pesar de la capacidad intr&#237;nseca del m&#250;sculo en la generaci&#243;n de fuerza ser igual entre los animales con y sin infarto, las ratas infartadas presentaban funci&#243;n ventricular deprimida. De ese modo, el propio proceso de remodelaci&#243;n, por los cambios geom&#233;tricos ocurridos, podr&#237;a comprometer la funci&#243;n global del coraz&#243;n<sup>28,29</sup>.</p>
      <p>Por el expuesto, la remodelaci&#243;n ventricular implica una serie de alteraciones morfol&#243;gicas, en respuesta a determinado est&#237;mulo o injuria. Inicialmente, ese proceso puede ser adaptativo, pero, a largo plazo, una de las consecuencias de la remodelaci&#243;n ser&#237;a el aparecimiento de progresiva disfunci&#243;n ventricular. Los mecanismos responsables de la deterioraci&#243;n funcional no est&#225;n completamente aclarados, pero pueden incluir alteraciones gen&#233;ticas, estructurales, bioqu&#237;micas y energ&#233;ticas.</p>
      <p>
        <bold>Factores determinantes de la remodelaci&#243;n ventricular</bold>
      </p>
      <p>El proceso de remodelaci&#243;n ventricular no ocurre de manera homog&#233;nea tras IAM. La prevalencia y la intensidad de ese proceso son influenciadas por cuatro factores:</p>
      <p>
        <bold>a) Caracter&#237;sticas morfol&#243;gicas del infarto </bold>
      </p>
      <p>Aunque la remodelaci&#243;n incide en diferentes tama&#241;os de lesi&#243;n isqu&#233;mica, se observa su predominancia en infartos de mayor tama&#241;o. De igual manera, parece haber, como prerrequisito, un tama&#241;o m&#237;nimo de lesi&#243;n (16%-20%) para que ocurra la remodelaci&#243;n. Otro factor se refiere al hecho de que, en raz&#243;n de la gran curvatura ventricular y del afilamiento de la pared anteroapical, la remodelaci&#243;n ocurre m&#225;s frecuentemente en esa regi&#243;n, t&#237;picamente en infartos transmurales<sup>3,30,31</sup>. </p>
      <p>
        <bold>b) Caracter&#237;sticas de la cicatrizaci&#243;n </bold>
      </p>
      <p>En las fases iniciales post-IAM ocurre un aumento importante del col&#225;geno en la zona infartada. Inicialmente, hay aumento del col&#225;geno tipo III. &#201;ste, reconocidamente, presenta menor resistencia a la deformaci&#243;n que el col&#225;geno tipo I, m&#225;s duro, que es predominante en corazones normales. Con el pasar del tiempo, hay descenso del col&#225;geno tipo III y elevaci&#243;n del tipo I. Se admite que el col&#225;geno neoformado tenga una consistencia menos firme que el col&#225;geno maduro. Ese hecho, asociado a la predominancia del col&#225;geno tipo III, determina el periodo de potencial vulnerabilidad de la cicatriz a las eventuales fuerzas deformantes. Por lo tanto, la cicatriz del IAM es un proceso din&#225;mico y sensible a intervenciones<sup>32</sup>. Como ejemplo, la administraci&#243;n de AINH o corticosteroides result&#243; en cicatrizaci&#243;n m&#225;s lenta, convirtiendo la regi&#243;n en m&#225;s susceptible a deformaciones, con agravamiento de la expansi&#243;n ventricular<sup>3</sup>. </p>
      <p><bold>c)</bold> Estr&#233;s hemodin&#225;mico. Con relaci&#243;n al estr&#233;s hemodin&#225;mico, se sabe que, durante la fase aguda del infarto, es com&#250;n ocurrieren flotaciones de las condiciones de carga con las cuales el coraz&#243;n trabaja. Ya est&#225; bien documentado que sobrecargas cardiacas interfieren en el proceso de remodelaci&#243;n<sup>3-5</sup>. Por ejemplo, en estudios experimentales, maniobras como la constricci&#243;n de la aorta, infusi&#243;n de metoxamina y ejercicio f&#237;sico precoz resultaron en mayor dilataci&#243;n ventricular en comparaci&#243;n a los animales control. Del mismo modo, seres humanos con hipertensi&#243;n arterial presentaron intensificaci&#243;n del proceso de remodelaci&#243;n<sup>3</sup>.</p>
      <p>
        <bold>d) Moduladores</bold>
      </p>
      <p>El infarto est&#225; caracterizado, en pr&#225;cticamente todos los casos, por el aumento de los niveles de diversos moduladores, como angiotensina II, endotelina 1, catecolaminas, factor de necrosis tumoral, interleucinas 1 y 6, factor de crecimiento transformador beta-1 y factor de crecimiento insulino-s&#237;mil 1. Se acepta que ese aumento tenga participaci&#243;n fisiopatol&#243;gica, ya que los diferentes moduladores reglan los eventos iniciales del infarto, como la reacci&#243;n inflamatoria y el proceso de cicatrizaci&#243;n. Adicionalmente, ellos resultan en efectos hemodin&#225;micos e inotr&#243;picos, que sirven como contraposici&#243;n a la p&#233;rdida de tejido contr&#225;ctil, contribuyendo a la estabilizaci&#243;n hemodin&#225;mica de los pacientes. En situaciones fisiol&#243;gicas, los niveles de los moduladores vuelven al normal tras aproximadamente una semana. En algunos casos, sin embargo, los niveles de esos factores pueden permanecer elevados. Modelos experimentales ya determinaron que niveles aumentados de los moduladores pueden tanto desencadenar como regular la remodelaci&#243;n cardiaca<sup>33,34</sup>. </p>
      <p>
        <bold>Historia natural de la remodelaci&#243;n ventricular</bold>
      </p>
      <p>Tras el infarto, cerca del 50% de los pacientes evolucionan con alg&#250;n grado de dilataci&#243;n ventricular izquierda. De esos, el 50% de los pacientes evolucionan con aumentos progresivos de la c&#225;mara ventricular, mientras que el 50% permanecen estables. De los pacientes que no presentan dilataci&#243;n en la fase aguda, cantidad a&#250;n no definida de pacientes, presentar&#225; el proceso de remodelaci&#243;n tras semanas, meses o a&#241;os luego del insulto isqu&#233;mico<sup>35</sup>.</p>
      <p>
        <bold>Diagn&#243;stico</bold>
      </p>
      <p>El diagn&#243;stico de la remodelaci&#243;n tras infarto, cl&#237;nicamente, est&#225; basado en la detecci&#243;n del aumento de la cavidad del ventr&#237;culo izquierdo. Para tanto, los m&#233;todos m&#225;s utilizados son el ecocardiograma, la ventriculograf&#237;a y la resonancia magn&#233;tica. Se acepta que la resonancia magn&#233;tica tiene mejor sensibilidad para la detecci&#243;n de alteraciones en el di&#225;metro de la cavidad ventricular izquierda. Sin embargo, en raz&#243;n de los costos y exigencias t&#233;cnicas, su aplicaci&#243;n cl&#237;nica es todav&#237;a limitada. Por ese motivo, en la pr&#225;ctica cl&#237;nica y aun en grandes ensayos cl&#237;nicos, el m&#233;todo m&#225;s utilizado para el diagn&#243;stico de remodelaci&#243;n es el ecocardiograma<sup>36</sup>. </p>
      <p>Otra forma de diagn&#243;stico, por ahora utilizada s&#243;lo en modelos experimentales y relatos cl&#237;nicos aislados, toma como base la detecci&#243;n de marcadores celulares que caracterizan el genotipo fetal. Entre esos, podemos citar: alteraciones de la cadena pesada de la miosina, con reducci&#243;n de la &#945; y aumento de la &#946;-miosina, aumento de la &#945;-actina, aumento de los p&#953;ptidos natriur&#233;ticos, disminuci&#243;n del GLUT-4 y aumento del GLUT-1, disminuci&#243;n de la SERCA-2a y aumento de la enzima conversora de la angiotensina<sup>3-5,8,37</sup>.</p>
      <p>
        <bold>Diagn&#243;stico diferencial</bold>
      </p>
      <p>El deslizamiento de haces musculares, caracter&#237;sticos de la expansi&#243;n del infarto, cuando realizado de forma abrupta e intensa, puede resultar en dolor precordial de variable magnitud. Otro aspecto para tomarse en consideraci&#243;n es que, aunque la expansi&#243;n no var&#237;a la cantidad de tejido necr&#243;tico, el deslizamiento de las fibras aumenta la superficie mioc&#225;rdica infartada. De esa manera, puede ocurrir intensificaci&#243;n del supradesnivelamiento del segmento ST en las derivaciones ya comprometidas o pueden ocurrir alteraciones del segmento ST en derivaciones inicialmente no comprometidas. Adicionalmente, en casos extremos, una cantidad de sangre puede quedar retenida en la regi&#243;n expandida durante la s&#237;stole, ocasionando la reducci&#243;n del volumen sist&#243;lico y el compromiso hemodin&#225;mico<sup>38</sup>.</p>
      <p>Por esas razones, el principal diagn&#243;stico diferencial de la expansi&#243;n es la extensi&#243;n del infarto (<xref ref-type="table" rid="tab01-body3">tabla 1</xref>). Mientras que la expansi&#243;n es un evento frecuente (50%), la extensi&#243;n ocurre en menos del 20% de los casos de IAM. La expansi&#243;n se manifiesta m&#225;s frecuentemente en los primeros d&#237;as del infarto, en grandes infartos transmurales de la pared anterior, al paso que la extensi&#243;n puede ocurrir en cualquier situaci&#243;n. Sin embargo, la principal distinci&#243;n entre las dos complicaciones es que la extensi&#243;n, por implicar nuevos focos de necrosis, sigue acompa&#241;ada de nueva elevaci&#243;n enzim&#225;tica<sup>38</sup>.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Factores de predicci&#243;n de la remodelaci&#243;n</bold>
      </p>
      <p>Como se dijo anteriormente, varios factores favorecen el aparecimiento de la remodelaci&#243;n, y los m&#225;s importantes son: infartos grandes, transmurales y anteriores, queda de la fracci&#243;n de eyecci&#243;n, ausencia o ineficacia de reperfusi&#243;n, fen&#243;meno de <italic>no-reflow</italic>, reoclusi&#243;n coronaria precoz, presencia de hipertensi&#243;n arterial y uso de AINH y corticoesteroide en la fase aguda del IAM (<xref ref-type="table" rid="tab02-body3">tabla 2</xref>)<sup>3,4,35</sup>. Recientemente, datos experimentales sugieren que el tabaquismo podr&#237;a intensificar la remodelaci&#243;n post-IAM<sup>39</sup>. De igual manera, reciente estudio cl&#237;nico sugiere que altos valores basales de glucemia tambi&#233;n pueden predecir remodelaci&#243;n<sup>40</sup>. Infartos peque&#241;os, infartos subendoc&#225;rdicos, infartos inferiores, reperfusi&#243;n presente y mantenida, evaluada por la resoluci&#243;n del segmento ST, microcirculaci&#243;n permeable, angina previa, ausencia de comorbidades y algunas medicaciones, todos ellos son factores que previenen el aparecimiento de remodelaci&#243;n<sup>3,4,35,41-43</sup>.</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0157-00013-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>Aspectos controvertidos sobre remodelaci&#243;n post-IAM</bold>
      </p>
      <p>A pesar del tema remodelaci&#243;n ser uno de los dos m&#225;s estudiados de los &#250;ltimos a&#241;os, a causa de su relevancia, varios aspectos permanecen controvertidos. </p>
      <p>En primer lugar, el infarto se caracteriza por muerte de tejido cardiaco, que se reemplaza por tejido de cicatrizaci&#243;n. As&#237;, conceptualmente, todo coraz&#243;n infartado cambia su composici&#243;n, o sea, sufre remodelaci&#243;n. Bajo el punto de vista cl&#237;nico, sin embargo, como ya se discuti&#243;, el t&#233;rmino remodelaci&#243;n, tras infarto, se lo utiliza com&#250;nmente para se&#241;alarse el aumento patol&#243;gico de la cavidad ventricular. </p>
      <p>Otro aspecto para tomarse en consideraci&#243;n es que, usualmente, el t&#233;rmino remodelaci&#243;n se utiliza para caracterizarse adaptaciones patol&#243;gicas. Sin embargo, no es siempre que se puede aplicar ese concepto. Por ejemplo, como se dijo anteriormente, el 50% de los pacientes tras infarto evolucionan con aumento de la cavidad ventricular en la fase aguda. Solamente la mitad de esos pacientes, sin embargo, presenta aumento progresivo de la cavidad y empeoramiento de la funci&#243;n ventricular. Los otros pacientes permanecen estables, tanto morfol&#243;gicamente como con relaci&#243;n a la funci&#243;n. Ese hecho sugiere que, en esos pacientes, el aumento de la cavidad puede ser adaptativo y sin consecuencias delet&#233;reas. Adicionalmente, existen diversos modelos de animales transg&#233;nicos que presentan hipertrofia y dilataci&#243;n ventricular en respuesta a diferentes sobrecargas, pero sin se&#241;ales de disfunci&#243;n ventricular o compromiso de la sobrevida<sup>44</sup>. Las evidencias acumuladas hasta el presente, por tanto, sugieren que, en determinadas situaciones, las alteraciones cardiacas caracter&#237;sticas de la remodelaci&#243;n pueden ser adaptativas adem&#225;s de contribuir al mantenimiento de la funci&#243;n ventricular, en respuesta a determinados est&#237;mulos (remodelaci&#243;n adaptativa o fisiol&#243;gica). Adicionalmente, se acepta que ese proceso adaptativo se modular&#237;a por medio de v&#237;as de se&#241;alizaci&#243;n celulares distintas (v&#237;a de la fosfatidil inositol 3-quinasa) de las v&#237;as implicadas en las remodelaciones patol&#243;gicas (fosfolipasa C, prote&#237;na quinasa C y calcineurina)<sup>45-47</sup>. </p>
      <p>Finalmente, es importante resaltar que el proceso de remodelaci&#243;n es extremamente complejo, resultando en alteraciones gen&#233;ticas, celulares y moleculares. Las alteraciones morfol&#243;gicas, como el aumento de tama&#241;o de la cavidad postinfarto, son solamente la forma por medio de la cual los cl&#237;nicos logran diagnosticar y estratificar el fen&#243;meno. As&#237;, hasta recientemente, estrategias que buscan la reversi&#243;n de la remodelaci&#243;n ten&#237;an como foco s&#243;lo la regresi&#243;n de las alteraciones morfol&#243;gicas. Por esa raz&#243;n, hasta el momento, existen dudas si la regresi&#243;n de las alteraciones morfol&#243;gicas sigue acompa&#241;ada de reversi&#243;n de las alteraciones gen&#233;ticas, bioqu&#237;micas y celulares. Datos m&#225;s recientes sugieren, sin embargo, que con algunas intervenciones en pacientes con insuficiencia cardiaca, la reducci&#243;n del espesor de la pared y del volumen de la cavidad del ventr&#237;culo izquierdo sigui&#243; acompa&#241;ada de disminuci&#243;n del tama&#241;o del miocito; recuperaci&#243;n del transito de calcio; mejora del citoesqueleto y de la v&#237;a &#946;-adren&#233;rgica; reducci&#243;n de la cantidad de col&#225;geno; y, posiblemente, alteraciones de las v&#237;as intracelulares responsables de la remodelaci&#243;n<sup>48</sup>. La reversi&#243;n cl&#237;nica de la remodelaci&#243;n, por tanto, parece ser evento real y se sigue de reversi&#243;n de las alteraciones fisiopatol&#243;gicas que modulan ese proceso.</p>
      <p>
        <bold>Prevenci&#243;n - atenuaci&#243;n - reversi&#243;n de la remodelaci&#243;n</bold>
      </p>
      <p>Por atenuarse tanto el tama&#241;o del infarto como la transmuralidad, la reperfusi&#243;n mioc&#225;rdica eficaz y duradera es la principal medida preventiva de la remodelaci&#243;n. Por no influenciar las caracter&#237;sticas de la cicatrizaci&#243;n, el AAS (&#225;cido acetilsalic&#237;lico) es la medicaci&#243;n antiinflamatoria de elecci&#243;n en la fase aguda del IAM. Otra medida es la reducci&#243;n del estr&#233;s parietal del ventr&#237;culo izquierdo; as&#237;, se debe evitar aumentos de presi&#243;n arterial en la fase aguda del IAM.</p>
      <p>Respecto a las medicaciones espec&#237;ficas, estudios experimentales mostraron que la utilizaci&#243;n precoz de los inhibidores de la enzima conversora de la angiotensina (IECA) atenuaba la remodelaci&#243;n<sup>2,49</sup>. Esas observaciones se confirmaron en estudios cl&#237;nicos<sup>50,51</sup>. De igual modo, en el modelo de la rata, la utilizaci&#243;n precoz de antagonistas de receptores AT1 de la angiotensina II atenu&#243; la remodelaci&#243;n y redujo la mortalidad post-IAM<sup>52</sup>. Posteriormente, estudios cl&#237;nicos no encontraron diferencia en las acciones de los ARAII con relaci&#243;n a los IECA, tras infarto<sup>53</sup>. A pesar del uso de betabloqueantes y antagonistas de la aldosterona tambi&#233;n seguir acompa&#241;ado de mejor progn&#243;stico<sup>54,55 </sup>en pacientes con disfunci&#243;n ventricular, con fracci&#243;n de eyecci&#243;n &lt;40%, no se conoce todav&#237;a el efecto de esas medicaciones en pacientes sin disfunci&#243;n ventricular, tras infarto. Por fin, debemos tomar en consideraci&#243;n que la revascularizaci&#243;n en pacientes con miocardio hibernante puede estar asociada a menor remodelaci&#243;n<sup>56,57</sup>. Otros abordajes terap&#233;uticos para prevenci&#243;n, atenuaci&#243;n o reversi&#243;n de la remodelaci&#243;n tras infarto, como la utilizaci&#243;n de la regeneraci&#243;n celular, los antagonistas de la vasopresina, los p&#233;ptidos natriur&#233;ticos, la sincronizaci&#243;n ventricular, los dispositivos mec&#225;nicos, los nitratos y las estatinas, necesitan a&#250;n confirmarse en grandes estudios cl&#237;nicos. </p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La remodelaci&#243;n ventricular es un evento relativamente com&#250;n post-IAM. La relevancia de la remodelaci&#243;n est&#225; asociada al hecho de que, adem&#225;s de resultar en mayor prevalencia de ruptura cardiaca, arritmias y formaci&#243;n de aneurismas, ese proceso puede modular el aparecimiento y la progresi&#243;n de disfunci&#243;n ventricular, insuficiencia cardiaca y muerte tras infarto. Otro hecho para se tomar en cuenta es que ese proceso no ocurre de forma homog&#233;nea en los pacientes con IAM. De esa manera, pacientes con remodelaci&#243;n ya diagnosticada, o con alto riesgo para desarrollarla, se deben tratar de manera agresiva, con la intenci&#243;n de prevenirse, atenuarse o aun reverterse dicho proceso. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
